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Among the parasitic diseases, schistosomiasis ranks second only to malaria in terms of 
socio-economic and public health impact. It is estimated that at least 229 million people, 
spread over 78 countries, required preventive treatment in 2018 [1]. Once a schistosome 
infection establishes, the parasite can live in the host for decades unless the infection is 
treated. In general, resistance towards schistosome infection is not acquired rapidly: even 
partial immunity requires many years of exposure, multiple infections and treatments 
to develop [2-6]. The main species of Schistosoma that infect humans are S. mansoni, S. 
japonicum and S. haematobium. The former two cause intestinal schistosomiasis, while 
the latter causes urinary schistosomiasis. Although different species lead to different 
presentations of the infection, the genome [7-9] and protein coding gene sequences 
[9] are highly similar, and antigens are strongly recognized by antibodies cross-species 
[10, 11]. The acute phase of schistosome infection is associated with an innate immune 
response followed by a Th1 dominant adaptive response. The chronic phase of infection 
begins as the parasite matures, and egg deposition occurs. During this time, the Th1 pro-
inflammatory response becomes down-regulated by the initiation of a more regulatory 
type Th2 immune response [12], limiting inflammation and immunopathology in order to 
allow parasite and host-survival. Nevertheless, granuloma formed around tissue-lodged 
eggs cause debilitating morbidity.
Current treatment of schistosomiasis relies mainly on the use of the chemical agent 
Praziquantel (PZQ), which is administered in mass treatment programs in endemic areas. 
The schistosomicidal activity of PZQ is believed to be due to calcium influx into the parasite, 
paralyzing adult worm muscles and damaging their tegument [13-17]. However, studies 
have also suggested that the disturbed calcium transport does not completely account 
for the effects observed after PZQ treatment [18]. Although the mechanism of action of 
PZQ is not fully established, it ultimately alters the conformation of the surface double 
lipid bilayer of schistosomes [19], after which exposure of antigens on the damaged 
worm tegument to the host immune system leads to the killing of the parasite [20, 21]. 
The host immune system triggered by dying worms alters the antibody and cytokine 
responses which provides short-term drug-induced resistance to infection [22, 23]. Since 
the resistance is only temporary and repeated PZQ treatment is required in endemic areas 





Antibody responses against schistosomes
The high prevalence of schistosomiasis in endemic populations indicates that natural 
immunity to schistosome infection is rare. Nevertheless, there are studies that showed 
that individuals in endemic areas can acquire immunity through years of exposure, and 
multiple rounds of reinfection and treatment [25, 26]. To date, there is still no proof or 
consensus to how an individual could possibly develop resistance to re-infection. Many 
studies have explored the host-schistosome interaction in order to reveal the connection 
between particular immune profiles and disease state. In the lab, radiation-attenuated 
schistosome cercariae vaccination has demonstrated high levels of protection in different 
hosts, from rodents [27-31] to primates [32-36]. It is known that in the schistosome infected 
host, antibodies are raised to numerous antigens of the parasite. The relevance of anti-
schistosome antibodies for protection has been demonstrated in passive serum transfer 
experiments: protection in naive mice can be achieved through passive transfer of serum 
from radiation-attenuated cercariae vaccinated rabbits and mice [37-39] and serum IgG 
has been shown to be responsible for this protection [37, 40]. The passively transferable 
protection has been shown for both S. mansoni [37, 40] and S. japonicum [39] infections. 
Additionally, it is proposed that the temporary resistance to infection following PZQ 
treatment is mediated by antibodies released when the dying worms expose antigens 
that are not normally encountered by the host immune system [41, 42]. In hosts protected 
by vaccination, the high anti-parasite antibody titers upon challenge [32-35, 43-45] and 
the necessity of functional B cells [46] support the hypothesis that antibodies are essential 
for developing a protective immune response. 
These observations have prompted researchers to identify antigenic molecules 
in schistosome infection/protection models that might form the basis for a practical 
and effective vaccine. In addition to peptide-directed responses, antibodies towards 
glycans are of particular interest for schistosomiasis, because antibodies directed towards 
antigenic glycan motifs on glycoproteins and glycolipids of the parasite are especially 
abundant [43, 47]. It has been shown that when periodate treatment is performed on 
schistosome antigenic mixtures, thereby destroying periodate sensitive glycans, infection 
serum antibody binding to the parasite antigen mixture was greatly decreased [43, 47]. 
As schistosomes mature through different life-stages in the host, their glycan expression 
goes through many changes [48]. Unlike proteins that are synthesized by a defined 
template coded in the corresponding gene, glycan biosynthesis is catalyzed indirectly by 
glycosyltransferases expressed in cells and tissues [49, 50]. Some glycans are expressed 
stage specifically in the parasite life-cycle, while many other glycans are found in multiple 




It has been shown that host antibodies elicited by Schistosoma antigens from different life 
stages can cross-react in a carbohydrate dependent manner [47].
Schistosome glycans
Schistosome-derived glycans have structural features that are different from mammalian 
cell derived glycans [53, 54], such as the lack of terminal sialic acid residues [54] and the 
abundant presence of terminal GalNAcβ1-4GlcNAc (LDN) branches on N-glycans rather 
than the Galβ1-4GlcNAc (LN) moiety [55, 56]. Furthermore, the fucosylation of terminal 
LDN motifs creates various non-mammalian antigenic motifs [48, 51, 56-58]. Common 
glycan epitopes expressed by schistosomes include terminal Galβ1-4(Fucα1-3)GlcNAc 
(LeX) [59], previously associated with Th2-inducing properties during schistosome 
infection [60-63]. The terminal LeX motif is highly expressed in cercariae N-glycans, but 
as the parasite develops into adult worms, non-fucosylated terminal LDN becomes more 
dominant [48] (Figure 1). Similarly, changes in the O-glycan and glycolipid repertoire 
occur during worm development.
Schistosome eggs also express glycoconjugates containing LeX and represent a 
major source of LeX antigens released in infected individuals [65]. Apart from terminal 
LeX, multimeric LeX (poly-LeX) is present on glycoproteins of worm excretions [66]. 
Other antigenic targets of schistosomes include core xylosylated and core fucosylated 
N-glycans. Core fucosylation can occur either with an α3 or α6 linkage, the former being 
a very antigenic epitope. Core xylose and core α3-fucose are not specific to schistosomes, 
but also occur in various other invertebrates [67, 68] and in plants [69-71] In schistosomes, 
core xylose occurs mainly in cercariae and miracidia [48], while core α3-fucose is 
exclusively found on N-glycans from miracidia and eggs. Alone or in combination with 
core xylose, core α3-fucose forms the major cross-reactive carbohydrate epitope that is an 
IgE target on a variety of plant-derived allergens [72-74]. Another set of antigenic glycan 
motifs include the (multi-)fucosylated terminal LN and LDN motifs. Multiple-fucosylated 
motifs are present in all life stages of schistosomes, mainly on O- or lipid-linked glycans 
and represent highly antigenic and characteristic epitopes in schistosomes [48, 51, 52, 
75]. Multiple-fucosylated LDN motifs can be further divided into the (Fucα1-3)GalNAcβ1-
4(Fucα1-3)GlcNAc (F-LDN-F) type that contain multiple α3-fucoses; and another type that 
contain one or more Fucα1-2Fuc motifs, such as (Fucα1-2Fucα1-3)GalNAcβ1-4(Fucα1-
2Fucα1-3)GlcNAc (DF-LDN-DF). Both these motifs are highly antigenic. The Fucα1-2Fuc-
containing motifs have so far only been found in the human schistosomes and the 
related bird schistosome Trichobilharizia ocellata [76], while F-LDN-F may be more widely 






Parasite-specific antibodies can be investigated in various hosts in cross-sectional or 
longitudinal studies. For ethical reasons, human individuals cannot be included in 
studies without also providing treatment, thereby limiting the possibility of longitudinal 
studies in endemic areas. Longitudinal studies of experimental animal infections hugely 
complement cross-sectional human studies by providing the possibility to follow antibody 
dynamics over the course of infection. 
When investigating host antibody responses to the parasite, apart from the 
antigen specificity, the type of antibodies elicited should be carefully evaluated. During 
infection, IgM, IgG, IgE as well as IgA towards schistosome antigens are elevated [77]. IgE 
is commonly recognized as beneficial for the Schistosoma infected host by facilitating 
cytotoxic reactions against schistosome larvae in vitro [78-80]. IgE antibody levels to 
Figure 1. Venn diagram summarizing the expression patterns of glycans and glycan motifs in 
different life stages of the parasite inside the definite host. This diagram has been adapted from a 




adult worms have shown to be significantly related to resistance to reinfection, while 
IgG4 antibodies in the same analysis were related to susceptibility of reinfection [81]. It 
is suggested that the delay in development of protective immunity against schistosomes 
is due to the slow build-up of parasite specific IgE in the host [81]. At the same time, 
IgG4 antibodies are regarded as an IgE blocking antibody that may down-regulate the 
immune system’s response against schistosome antigens [77, 81, 82] and the IgE/IgG4 
ratio appears to be an important indicator for susceptibility to reinfection [81, 83, 84]. 
IgM and IgG2 have also been regarded as blocking antibodies that prevent the binding 
of antibodies of effective isotypes to the same epitope, thereby inhibiting cytotoxicity 
mediated towards the parasite by eosinophils or other cells [82, 85-88]. These ‘blocking 
antibodies’ have been found to react with glycan epitopes expressed both on schistosome 
eggs and schistosomula [85]. Moreover, the titers of these blocking antibodies were found 
to decline with age [86, 87], which may explain why young children are more susceptible 
to posttreatment reinfection. In contrast, IgG1 and IgG3 against schistosome glycans 
have been found to be potent inducers of eosinophil mediated cytotoxicity against 
schistosomula, thus possibly are the protective IgG isotypes. 
The association of glycan-specific antibody isotypes and subclasses with protection 
have not been studied extensively. Nevertheless, it is clear that specific IgG towards 
antigenic schistosome glycans, including LeX, LDN, GalNAcβ1-4(Fucα1-3)GlcNAc (LDN-F) 
and core fucose and xylose determinants are elicited by S. mansoni infected hosts [89-
91]. In particular, infected mice respond to the LDN and LDN-F epitopes with a Th2 type 
immune response characterized by the presence of IgM, IgG1 and IgG3, but not of the IgG2 
subclass [75]. Infected humans also generate IgM, IgG and IgA towards LDN, LDN-F and 
LeX [92]. An age-related influence towards anti-glycan antibody responses was observed 
in schistosome infected hosts: children, associated with being less resistant to reinfection 
than adults, elicit higher titers of antibodies against LDN-DF and F-LDN [93, 94].
It is worth noting that the anti-glycan antibody responses have been suggested in 
some studies to be a ‘smokescreen’ response that diverts the host immune system away 
from attacking vulnerable parasite antigens [43, 47]. On the other hand, studies have also 
shown that antigenic schistosome glycans could be involved in developing a protective 
response [75, 89, 95]. These opposing views can result from generalization, disregarding 
the many types and structures of glycan targets present in schistosomes, and/or the 
nature of antibodies raised against the target. Unravelling the complex interplay between 
the antibody responses and the identification of the individual antigenic glycan motifs in 
schistosomes will help us better understand their role in the host-parasite interactions, 







Using glycan microarrays to study 
antibody-glycan interactions
Recent advances in chromatography and mass spectrometry-based approaches for 
isolation and characterization of glycans together with specific chemical and enzymatic 
degradation methods have made it possible to identify many schistosome glycans and 
glycan motifs. The glycome of S. mansoni has been described in detail [48]. Together with 
immunofluorescent staining of the parasite with anti-glycan monoclonal antibodies [51, 
52, 92], there is good understanding of the structure of different glycans, when they are 
expressed, as well as whether they are present on the immediate host-parasite interface. 
Although the full glycome of the other two Schistosoma species have not been described 
yet, earlier findings have suggested that they are highly similar to that of S. mansoni [96-
98].
The separated and characterized parasite glycans can be printed on microarrays, 
creating ‘shotgun glycan-microarrays’ [94, 99, 100] that can be interrogated using lectins, 
monoclonal antibodies or serum/plasma to further characterize the glycan antigens and 
their binding partners. Shotgun glycan microarrays are valuable for they offer a wider 
range of glycan elements, including highly complex structures isolated from the organism 
that are not technologically feasible to synthesize. On the other hand, synthetic glycan 
arrays [89, 101] can complement the shotgun-glycan microarrays by a) identifying single 
antigenic motifs in situations where multiple structural motifs exist in the natural glycan 
and b) identifying the antigenicity of glycans that are not available in sufficient quantities 
or cannot be purified from the native source. The application of glycan microarray 
technology has made it possible to study anti-glycan antibody responses to parasite 




Scope of this thesis
A better understanding of anti-glycan antibody responses during infection and the 
development of schistosome resistance could improve current schistosomiasis diagnostic 
methods as well as identify potential vaccine targets.
In the first part of this thesis, the antibody responses towards schistosome glycans 
are studied in different models by the use of glycan-microarrays. In Chapter 2, the anti-
glycan IgG and IgM response in infected rhesus macaques is studied over time while 
infected rhesus macaques gradually develop immunity towards schistosomiasis. Chapter 
3 describes a vaccine-induced model for protection against schistosome infection, where 
the anti-glycan IgG and IgM response of radiation-attenuated cercariae vaccinated 
olive baboons was studied by glycan microarray. These two longitudinal studies reveal 
the schistosome glycan motifs recognized by a host as well as the anti-glycan antibody 
dynamics during the development of protection against schistosomiasis. It has been 
described that the development of anti-glycan IgG response is important for developing 
protection. Yet, chronically infected individuals also develop IgG towards schistosome 
antigens. Different IgG subclasses have different immunological properties that may or 
may not lead to protection. However, the IgG subclass responses towards glycan motifs 
have not previously been described. Thus, in Chapter 4, the IgG subclass responses of 
human subjects from a schistosome endemic village is investigated.  
The last part of this thesis builds on the fact that fucosylated LDN is an antigenic 
glycan motif recognized by all schistosome infected hosts. However, it’s role in protection 
is unknown. Chapter 5 describes an immunization plus challenge experiment where rats 
were immunized with single- and double-fucosylated LDN motifs conjugated to BSA.  The 
worm burden after cercarial challenge of glycoconjugate immunized rats was compared 
with unconjugated BSA-immunized rats and the anti-glycan IgG and IgM response was 
measured. 
Together, these chapters reveal antigenic schistosome glycan motifs, as well as the 
corresponding antibody dynamics in the context of infection and the development of a 
protective immune response towards schistosome infection. This information provides 
insights into the possibility of using glycans as diagnostic and vaccination candidates 
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Background: Human immunity to Schistosoma infection requires many years of 
exposure, and multiple infections and treatments to develop. Unlike humans, rhesus 
macaques clear an established schistosome infection naturally at the same time acquiring 
immunity towards re-infection. In macaques, schistosome egg production decreases 
after 8 weeks post-infection and by week 22, physiological impairment of the worm 
caused by unclarified antibody-mediated processes is observed. Since strong antibody 
responses have been observed against schistosome glycan antigens in human and animal 
infections, we here investigate if anti-glycan antibodies are associated with immunity 
against schistosome infections in macaques.
Methods: We used a microarray containing a large repertoire of glycoprotein- and 
glycolipid-derived glycans from different schistosome life stages to analyze anti-glycan 
serum IgG and IgM from S. japonicum-infected macaques during the course of infection 
and self-cure. We also used an in vitro schistosomula assay to investigate whether macaque 
sera containing anti-glycan antibodies can kill schistosomula.
Conclusions/significance: Antibody responses towards schistosome glycans at week 
4 post-infection were dominated by IgM while IgG was high at week 8. The profound 
increase in IgG was observed mainly for antibodies towards a large subset of glycans that 
contain (multi-)fucosylated terminal GalNAcβ1-4GlcNAc (LDN), and Galβ1-4(Fucα1-3)
GlcNAc (LeX) motifs. In general, glycans with a higher degree of fucosylation gave rise 
to stronger antibody responses than non-fucosylated glycans. Interestingly, even though 
many IgG and IgM responses had declined by week 22 post-infection, IgG towards 
O-glycans with highly fucosylated LDN motifs remained. When incubating macaque 
serum with schistosomula in vitro, schistosomula death was positively correlated with 
the duration of infection of macaques; macaque serum taken 22 weeks post-infection 
caused most schistosomula to die, suggesting the presence of potentially protective 
antibodies. We hypothesize that IgGs against highly fucosylated LDN motifs that remain 
when the worms deteriorate are associated with infection clearance and the resistance to 
re-infection in macaques. 
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Introduction
Schistosomiasis is a debilitating parasitic disease caused by members of the helminth 
genus Schistosoma (S.), with S. mansoni, S. japonicum and S. haematobium being the 
most prevalent human species. Once Schistosoma infection establishes, mature worms 
can live up to 30 years in the host until treated [1]. Many studies on human Schistosoma 
infection have indicated that resistance to Schistosoma infection can be acquired, but 
this is age-dependent and requires many years of exposure to the parasite, and multiple 
infections and treatments to develop [2]. Praziquantel (PZQ) is widely used to treat human 
schistosomiasis by paralyzing adult worm muscles and damaging the tegument [3]. This 
exposes worm antigens to the host immune system [4] and leads to immune-mediated 
killing of the parasite. The immune responses triggered by degenerating worms can alter 
antibody and cytokine responses and provide short-term drug-induced resistance to re-
infection [5, 6]. Since this resistance is short-lived, people in endemic areas still require 
repeated administration of PZQ [7]. An effective elimination strategy would likely require 
the incorporation of a vaccine to immunize against schistosome (re)infection [8, 9]. 
Rhesus macaques are permissive hosts for Schistosoma infections. In rhesus 
macaques infected with S. japonicum, oviposition occurs 34-36 days after exposure and 
the peak egg excretion occurs 7-15 weeks post-infection [10]. However, unlike Schistosoma 
infections in humans where the infection persists with heavy egg shedding for decades, 
rhesus macaques show various signs of resistance to infection four months after infection 
[11]. Marked decrease in eggs detected in the feces of macaques is observed 11 weeks 
post-infection, correlating to the vulnerable health status of the female worms, as seen 
by the diminished body lengths and size of sexual organs [10]. The rate of adult worm 
recovery from macaques also greatly decreases to 32% 19 weeks post-infection and 9% by 
the 42nd week [10]. The same type of worm degeneration and diminished oviposition is 
observed in S. mansoni-infected rhesus macaques [12]. However, the decline in fecal egg 
output was observed at a slightly earlier time point: 9 weeks post-infection. In addition 
to eliminating the worms from the body, rhesus macaques were found to be completely 
resistant to secondary infection 21 weeks after primary infection when challenged with 
schistosome cercariae, even though the macaques were still in the process of clearing the 
primary infection [13]. It has been postulated that rhesus macaques clear schistosome 
infection and become resistant to re-infection through an antibody-mediated process, 
based on a strong inverse relationship observed between the intensity of IgG response 
and worm burden [12]. Additionally, when blood feeding worms were cultured in vitro 
with serum of macaques with low worm burden, stunted growth was observed for these 




kill schistosomula in vitro [14, 15]. Recently, Li et al. have suggested that antibody binding 
to adult worm esophagus blocks nutrient uptake and eventually lead to starvation of 
worms [16]. In view of the long time taken for the worms to degenerate, it is likely that 
the mechanism of clearance does not involve complement fixation [17] but a sustained 
antibody-mediated process that affects the normal physiology of worms.
An abundance of antibodies is generated in Schistosoma-infected hosts that bind 
to glycans from schistosome glycoproteins and glycolipids [18-24]. Localization studies 
with glycan-directed monoclonal antibodies [25, 26] and glycomic profiling by mass 
spectrometry [27] have indicated that Schistosoma mansoni glycosylation exhibits stage-
specific changes during the life cycle. For example, the structural motifs Fucα1-3GalNAcβ1-
4GlcNAc (F-LDN) and Fucα1-3GalNAcβ1-4(Fucα1-3)GlcNAc (F-LDN-F) are abundantly 
expressed in cercarial and egg glycoproteins but could hardly be detected in adult worm 
glycoproteins [26]. Nevertheless, multi-fucosylated GalNAcβ1-4GlcNAc (LDN) motifs are 
present in glycolipids throughout the whole life cycle. Cercarial N-glycans are found to be 
dominated by the Galβ1-4(Fucα1-3)GlcNAc (LeX) termini [28]. However, the expression of 
LeX by cercariae is rapidly lost after their transformation into schistosomula, while LDN 
motifs gradually become predominant in maturing worms [27]. While some glycan types 
and motifs are expressed in a stage-specific manner, cross-reactive glycans exist between 
different life stages. It has been shown that many antibodies elicited by egg glycans are 
cross-reactive with glycans expressed on the surface and secretions of cercariae [29]. 
Apart from cross-life stage similarities, there are also high cross-species similarities in 
schistosomes. S. japonicum and S. mansoni have a 86% homology in protein coding gene 
sequences [30] and S. mansoni-infected human sera recognize S. japonicum proteins on 
a schistosome protein array [31] and vice versa [32]. Although S. mansoni glycosylation is 
better characterized than that of S. japonicum, studies have suggested that the glycans 
expressed by the two species are highly similar [33, 34]. 
Recently, anti-glycan responses in Schistosoma infected humans and animals have 
been studied using glycan microarray approaches [19, 22-24]. With the aim of identifying 
possible glycan targets involved in clearance of Schistosoma and resistance to reinfection, 
we here analyzed anti-glycan antibodies in a set of S. japonicum-infected rhesus macaque 
sera collected over a period of 22 weeks, using a microarray containing a large repertoire 
of N-, O- and glycosphingolipid (GSL) derived glycans isolated from S. mansoni larvae, 
adult worms and eggs [19, 23, 35] complemented with a synthetic microarray containing 
a set of relevant core-modified N-glycans [35]. After obtaining the antibody profile of 
schistosome-infected rhesus macaques at different infection stages, we incubated these 
sera with in vitro transformed schistosomula to study the effect of antibodies on parasite 
survival. Our work provides new insights into glycan motifs that may be the targets of a 
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protective antibody response to Schistosoma infection.
Materials and Methods
Ethics statement
The housing conditions, experimental procedures and animal welfare of the monkeys used 
in the study were in strict accordance with the national guidelines for the Care and Use 
of Animals established by the Chinese National Animal Research Authority and applied 
by the Institutional Animal Care and Use Committee (IACUC) of the Kunming Institute of 
Zoology, Chinese Academy of Sciences (CAS). The experimental protocol was approved 
by the Ethics Committee of Kunming Institute of Zoology, CAS (ID SYDW-2011017). The 
study used six adult male rhesus macaques (Macaca mulatta) from the captive-breeding 
colony at the Kunming Primate Research Center, CAS. They were group-housed prior to 
the experiment but then singly after infection for fecal sampling purposes. The separate 
cages were arranged in one large room to allow the monkeys visual, olfactory and auditory 
interactions with each other. Food and water were available ad libitum and vitamins were 
provided. The animals were also provided with environmental enrichment, such as toys 
designed especially for monkeys, to promote psychological well-being. The design and 
execution of the study complied with the recommendations of the Weatherall report 
(2006) on “The use of non-human primates in research”, which specifically mentions the 
continuing requirement for their use in schistosome research.
Sera
Rhesus macaques were anaesthetized with ketamine hydrochloride (6 mg/kg body weight. 
Gutian Pharmaceutical Corporation, Fujian China) and infected percutaneously with 600 
cercariae of S. japonicum via the shaved abdominal skin for 30 minutes. S. japonicum 
cercariae were obtained from patent Oncomelania hupensis snails kept at the Jiangsu 
Institute of Parasitic Diseases (Wuxi, China) [16]. Blood was obtained by intravenous 
sampling at 5 time points, week 0, 4, 8, 14 and 22, stood at room temperature for 1 hour (h) 
to clot, and kept overnight at 4°C to facilitate clot retraction before serum was recovered 
for storage at -20°C. All animals were individually inspected daily. Those showing signs of 
diarrhea were given oral dehydration therapy as required
Materials
Cy3 conjugated goat anti-human IgG (Fc-specific) and Alexa Fluor 647 conjugated goat 
anti-human IgM (μ chain specific) were from Invitrogen (The Netherlands). BSA and 




Glycan microarray construction and analysis
The shotgun glycan microarray was constructed as described previously [19, 23]. A 
selection of fractions was analyzed in this study compared to those previously described 
and contained reverse phase HPLC fractions of glycans isolated from cercariae (82 
N-glycan fractions, 114 O-glycan fractions and 21 glycolipid glycans), adult worm (83 
N-glycan fractions, 39 O-glycan fractions) and egg (62 egg N-glycan fractions, 110 soluble 
egg antigen O-glycan fractions and 12 glycolipid glycans). Additionally, 24 blank spots 
with spot buffer were included for array background control. Each glycan fraction was 
immobilized on a glass slide in triplicate. 
The synthetic array used in this study contained a collection of core-xylosylated and 
core-α3 and α-6 fucosylated N-glycans with various core extensions [35]. The synthetic 
N-glycans were immobilized to N-hydroxysuccinimide (NHS)-activated glass slides 
via a C5 amino linker. Unreacted NHS groups were quenched by blocking with 50 mM 
ethanolamine in 50 mM sodium borate buffer, pH 9.0 for 1 h. The slides were then washed 
with PBST, PBS and MilliQ water, dried and then stored at -20°C. The slides were defrosted 
upon use, followed by serum sample incubation, as described in the following section. 
Binding assay
The glycan-microarray binding assay followed the protocol as described by van Diepen et 
al. [19, 23]. Briefly, the microarray slide was blocked with 2% BSA, 50 mM ethanolamine in 
PBS. Serum samples were diluted 1:100 in PBS-0.01% Tween20 with 1% BSA. Cy3-labeled 
anti-human IgG and Alexa Fluor 647-labeled anti-human IgM were diluted 1:1000 in PBS-
0.01 Tween20 to detect bound serum antibodies on the slide. All washing steps were 
performed with successive rinses with PBS-0.05% Tween20 and with PBS. The last washing 
step was finished by an additional wash with milliQ water and the slides were dried and 
kept in the dark until scanning. 
Scanning and data analysis
A G2565BA scanner (Agilent Technologies, Santa Clara, CA) was used to scan the slides 
for fluorescence at 10 um resolution using lasers at 532 nm and 633 nm. Total IgG was 
detected at 532 nm and IgM at 633 nm, the 2-AA label does not fluoresce at these 
wavelengths. Data and image analysis was performed with GenePix Pro 7.0 software 
(Molecular Devices, Sunnyvale, CA). Spots were aligned and re-sized using round features 
with no CPI threshold. Background-subtracted median intensities were averaged per time 
point and processed as described by Oyelaran et al. [36]. Datasets were log2 transformed 
to remove the basic trends of variance. A hierarchical clustering analysis (HCA, complete 
linkage clustering using Euclidean distance metric) was performed to group associated 
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glycan fractions using MultiExperiment Viewer v4.5. To identify statistically different 
IgG and IgM response towards glycan fractions, a paired sample t-test was performed 
using SPSS. A P value < 0.05 was used to identify glycan fractions that were differentially 
recognized by serum IgG and IgM antibodies. 
Schistosomula transformation 
Freshly shed cercariae from snails were centrifuged at 440 x g for 5 min. The buffer 
was replaced with 37°C M199 medium supplemented with 1:100 1M HEPES pH7.4, 1x 
antibiotic antimycotic solution (ABAM), 1.5 mM glutamine and 10% FCS. The cercariae 
were resuspended with the medium and incubated at 37°C for 20 minutes in order to 
facilitate cercarial transformation into schistosomula. The incubated tube was shaken 
regularly to avoid sedimentation. Afterwards, the parasites were transferred to a petridish 
and put on an orbital shaker. During orbital shaking, schistosomula that collect at the 
center of the petridish were taken out with a pipette, while swimming cercaria and tails 
that collect at the sides of the petridish were left behind. Isolated schistosomula were 
resuspended in supplemented M199 medium and cultured in a microtiter plate at 37°C in 
a humidified atmosphere with 5% CO2. 
Schistosomula killing assay
A total of 400 transformed schistosomula was cultured in each well of a flat bottom 96 well 
plate containing 100 ul of M199 medium supplemented with HEPES pH7.4, 1x antibiotic 
ABAM, 1.5mM glutamine and 10% FCS at 37°C in a humidified atmosphere with 5% CO2. 
At 3 hours post transformation, 55 ul of medium was carefully taken out of the wells 
and 5 ul of sera was added to each well to create a 1:10 serum dilution. Where required, 
sera were treated by incubation at 56°C for 45 minutes to inactivate complement. Each 
treatment was done in duplicate. Immediately after treatment, the plate was observed 
under a microscope to detect gross changes, such as schistosomula agglutination. The 
effect of treatment and induction of schistosomula killing was measured at 24 h and 48 h 
after treatment. Morphological changes were observed by using brightfield microscopy 
while schistosomula integrity was determined by fluorescent microscopy (Leica) using 
propidium iodide (PI) [37] staining at 10 ug/ml. Multiple photographs were taken of each 





IgG and IgM responses against schistosome glycans 
We incubated sera from six S. japonicum-infected rhesus macaques with a schistosome 
glycan microarray to investigate their anti-glycan antibody responses over a time course 
of 22 weeks. Figure 1 shows averaged IgG and IgM responses of rhesus macaques towards 
N-, O- and lipid-glycans isolated from S. mansoni cercariae, worms and eggs. 
At the onset of infection, weak IgM signals against some glycans present on the 
schistosome array were detected in macaque serum, probably due to low levels of 
naturally occurring anti-glycan antibodies [38]. At week 4, strongly increased IgM was 
found binding to cercarial N- and O-glycans, egg-derived N-glycans and GSL glycans. 
Noteworthy, even though no eggs are produced 4 weeks post-infection, IgM antibodies 
were found against egg-derived glycans containing LeX and (fucosylated) LDN motifs; 
these glycan motifs have previously been shown to be shared with cercariae [26, 33, 34]. 
At 8 weeks post-infection, when oviposition was highest, maximum anti-glycan IgM titers 
were observed, especially against GSL-glycans and egg and cercarial O-glycans. These 
responses decreased at 14 weeks post-infection. At week 22, responses that persisted 
were very similar to those at week 4, but at a lower intensity. Notably, the IgM response at 
week 22 post-infection remained positive against a broad range of GSL glycans.
 In contrast to IgM, IgG of infected macaques directed towards schistosome glycans 
was negligible at week 0, while a slight induction of an IgG response against cercarial 
O-glycans and GSL glycans could be detected at week 4 post-infection. At 8 weeks post-
infection, a strong rise of IgG towards egg and cercarial N- and O-glycans was observed. 
Additionally, IgG against GSL glycans and cercarial O-glycans remained strongly positive 
at week 14 and week 22, while responses to egg O-glycans were greatly reduced during 
this period. Schistosoma GSL glycans had high IgG and IgM binding at week 22. 
IgG and IgM response profiles of S. japonicum-infected 
macaques
Following the IgG and IgM response patterns, we performed a hierarchical clustering 
analysis to group glycans with similar antibody response profiles. Anti-glycan antibody 
responses were corrected for baseline (week 0) intensity to obtain the intensity of 
response induced by infection. Four different glycan clusters were identified, based on 
IgG dynamics, namely IgG-C1, IgG-C2, IgG-C3 and IgG-C4 (Fig. 2A) and six clusters for IgM 
dynamics, namely IgM-C1, IgM-C2, IgM-C3, IgM-C4, IgM-C5 and IgM-C6 (Fig. 2B). 
IgG-C1 contained glycans that were highly antigenic; antibodies against this cluster 
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Figure 1. Averaged serum IgG and IgM response from schistosome-infected macaques to glycans 
isolated from different life stages of schistosomes. The horizontal axis indicates N- and O-glycan 
fractions from Schistosoma cercariae, adult worms, and eggs. Schistosome GSL glycans are shown as a 
group irrespective of the life stage. Average background-subtracted median fluorescence intensities 
are shown for IgG and IgM over a time course of 22 weeks. Each bar corresponds to antibody binding to 




reached a maximum at week 8 post-infection, and remained until week 22 (Fig. 2C). 
IgG-C2 elicited antibody responses that became positive between weeks 4 and 8, again 
remaining positive until week 22. In terms of antibody binding based on the detected 
fluorescence intensity of the array, there was a higher amount of IgG antibodies binding 
to glycans in IgG-C1 than in IgG-C2. Clusters IgG-C3 and IgG-C4 were smaller in size and 
glycans in these clusters did not yield high IgG signals. Antibodies against glycans in 
IgG-C3 peaked at week 8 post-infection and quickly decreased thereafter, while glycans 
in IgG-C4 did not appear to induce any IgG in macaques during the infection. A closer 
look at the type of glycans present in each cluster reveals that IgG-C1 and IgG-C2 were 
dominated by O-glycans and GSL glycans, while IgG-C3 and IgG-C4 contained mostly 
N-glycans (Fig. 2D and Table S1A). 
Six response profiles were identified for IgM binding. There were three clusters that 
remained positive at week 22, namely IgM-C3, IgM-C4 and IgM-C5 (Fig. 2E). Glycans in 
IgM-C3, -C4 and -C5 were mainly O-glycans derived from cercariae and eggs and lipid 
derived glycans (Fig. 2F and Table S3A). On the other hand, clusters IgM-C1, -C2 and -C6, 
with no sustained antibody binding at week 22 post-infection, contained a majority of 
N-glycans. IgM-C1, -C2 and -C6 differed in the onset of IgM binding: while glycans in 
IgM-C2 were bound by macaque serum IgM generated at week 4 and later, glycans in 
IgM-C6 only had IgM binding at week 8. IgM-C1 had no infection-induced IgM binding at 
any timepoint.
Previously, the glycan composition of each glycan fraction printed on the array has 
been determined by mass spectrometry. Based on described structural glycan motifs in 
the literature [20, 23, 24, 27, 28, 33, 34, 39, 40], the most likely glycan structures for different 
glycan compositions were deduced for both IgG and IgM. We have summarized the most 
abundant glycan motifs for each IgG cluster, as well as the representative fractions in 
each IgG cluster in Table S1B and Table S2. The most common glycan motifs in IgG-C1 and 
IgG-C2 were the LeX and multi-fucosylated LDN motifs.
O-glycan specific structural elements played an important role in the cluster 
formation of IgG-C4 and IgG-C2. For example, the Schistosoma specific O-glycan core 
Galβ1-3(Galβ1-6)GalNAc is sometimes found with an additional β1-6Gal on either the 
Galβ1-3 or the Galβ1-6 [41]. This structural element is found in cercariae-derived O-glycan 
fractions 3.4 and 6.6, and was one of the representative structures in IgG-C2 (Table 
S2). Another example of an O-glycan specific motif was the multi-fucosylated Galβ1-
4GalNAcβ1-4GlcNAc (Gal-LDN) motif [23, 42]. Compared to IgG-C2, IgG-C1 glycans were 
more complex and were in general longer in glycan chain length. For example, the di-LeX 
motif was expressed in both IgG-C1 and IgG-C2, but the tri-LeX motif was uniquely present 
in IgG-C1. In general, LDN motifs in IgG-C1 contained a higher extent of fucosylation; the 
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Figure 2. Hierarchical clustering analysis of macaque serum anti-glycan antibody responses over 
22 weeks after infection with Schistosoma japonicum. Antibody median fluorescence intensity was 
corrected for baseline and log2 transformed. The reduction in antibody binding is indicated in blue, while 
the increase is indicated in red. Four major clusters were identified based on IgG response dynamics over 
time (A), and six major clusters for IgM (B). The median fluorescence intensity at each time point was 
averaged to obtain a response profile curve for each IgG (C) and IgM (E) major cluster. Distribution of 
IgG and IgM cluster profiles based on glycan origin is shown in (D) and (F), respectively. Worm N, worm 
derived N-glycan; Cerc N, cercaria derived N-glycan; Egg N, egg derived N-glycan; Worm O, worm derived 




previously defined DF-LDN-TF structure in cercarial O-glycan fraction 15.6 [23] was an 
antigenic motif uniquely found in cluster IgG-C1 (Table S2).  In contrast to clusters IgG-C1 
and IgG-C2 that were dominated by O–glycans (Table S1A), IgG-C3 and IgG-C4 consisted 
of 75% and 88% N-glycans, respectively, which were mostly worm-derived (Fig. 2D). Most 
of the N-glycans in IgG-C4 did not have antigenic elements, but mainly expressed terminal 
Galβ1-4GlcNAc (LN), mannose and terminal GlcNAc (Gn) motifs (Table S2). Compared to 
IgG-C4, IgG-C3 contained a higher number of fucosylated motifs, which led to a more 
antigenic response profile, although these responses were not sustained in time. 
The clusters that had the highest amount of and long sustained IgM binding were 
IgM-C3 and -C4. The glycans in IgM-C3 and –C4 were abundant in antigenic motifs, 
such as LeX, (F)Gn, multiple fucosylated LDN and O-glycan-specific motifs b1-6 Gal and 
(fucosylated) Gal-LDN motifs (Table S3B). IgM-C5 was a small cluster that was also IgM 
positive at week 22, but had less IgM binding than IgM-C3 and IgM-C4. It contained 42% 
N-glycans, 58% O-glycans and no GSL glycans (Table S3A). IgM-C2 showed a response 
profile that was not recognized as a significant cluster in IgG. Glycans in IgM-C2 had 
IgM binding between week 4 and 14 and became undetectable at week 22; this cluster 
contained 64% N-glycans, 35% O-glycans and 2% lipid derived glycans with many glycans 
expressing the LeX motif.
When comparing IgG and IgM clusters, it was interesting to see that there was 
a sharp difference between the IgG antigenicity of N-glycans and O-glycans. A vast 
majority of N-glycans had no IgG binding at week 22 post-infection and were grouped 
in low antigenic clusters IgG-C3 and IgG-C4. On the other hand, IgM responses to many 
N-glycans were positive at week 22. A common pattern in IgG and IgM response profiles 
was that highly fucosylated glycan motifs led to higher serum antibody levels compared 
to less fucosylated structures. The more antigenic the cluster was, the more fucosylated 
motifs it contained. This effect was especially pronounced in IgG profiles. 
Infected macaque sera target core xylose/core α3-fucose  
In addition to the shotgun array, we tested the same set of macaque sera on a synthetic 
array previously described by Brzezicka et al.[35]. This array contains a collection of core-
xylosylated and core-fucosylated N-glycans. Several of these defined synthetic glycan 
structures are present in schistosomes, including a number of core α3-fucose modified 
N-glycans which were not present on the shotgun array. Figure 3 shows IgG responses of 
macaque sera towards the synthetic glycan array over time (Fig. 3). At week 0 and week 
4 post-infection, there were minimal IgG responses against core α3-fucose and terminal 
LDN structures; the IgG response towards LDN on the α6 branch is stronger than towards 
LDN on the α3 branch. At week 8 post-infection, there was strongly increased IgG against 
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Figure 3. Averaged serum IgG responses from S. japonicum-infected rhesus macaques to synthetic 
core modified N-glycan fractions. The horizontal axis depicts core modified N-glycan fractions 
that have been synthesized and described by Brzezicka et al. [35]. Average median fluorescence 
intensities are shown for S. japonicum-infected macaque serum IgG over a time course of 22 weeks. 
Each peak along the vertical axis corresponds to each individual glycan fraction printed on the 
glycan microarray. Core xylosylated, core α6-fucosylated and core α3-fucosylated structures are 
indicated. Within core xylosylated structures, those that have additional monosaccharides on the 




structures with core xylose and core α3-fucose, either in combination with core α6-fucose, 
or alone. Interestingly, the absence of α6-mannose on xylosylated structures reduces IgG 
binding. Additionally, IgG binding was also reduced in xylosylated structures where the 
α3 branch was occupied by additional monosaccharides. At week 14 post-infection, a 
general decrease in IgG responses towards antigenic core modified glycans was observed. 
Those IgGs that remained at week 14 and 22 bound to unhindered core xylose and core 
α3-fucose-containing glycans. IgG binding to the xylosylated N-glycan core was similarly 
observed on the shotgun array peaking at week 8 post-infection and then decreasing (Fig. 
S1). Nevertheless, the amount of IgG binding to xylosylated structures was much lower 
than to other antigenic motifs on the same array, such as the fucosylated terminal LDN 
motifs. 
An interesting observation on the synthetic array was IgG binding to glycans G82 
and G84, which had a Fucα1-3GlcNAcβ1,4(fucα1-3)GlcNAc modified N-glycan core that 
has been previously identified in H. contortus N-glycans [43] but not in schistosomes 
[27]. IgG towards G82 and G84 remained highly positive at week 22. We tested whether 
these glycans are recognized by an antibody against the structurally related Fucα1-
3GalNAcβ1,4(fucα1-3)GlcNAc (F-LDN-F) motif, as the anti-F-LDN-F response is also 
sustained at week 22. However, anti-F-LDN-F monoclonal antibody 128-1E7 did not bind 
to G82 and G84 (Fig. S4), meaning that the Fucα1-3GlcNAcβ1,4 (Fucα1-3)GlcNAc modified 
N-glycan core is not cross-reactive with the F-LDN-F motif. It is likely that antibodies 
recognizing glycans G82 and G84 are recognizing core α3-fucose irrespective of the 
presence or absence of a second α3-fucose. 
Macaque sera at later infection time points kill 
schistosomula in vitro with higher effectiveness 
 To investigate the potential functional involvement of macaque serum antibodies in 
resistance to infection by promoting schistosomula killing, we incubated sera collected 
at different infection time points with live in vitro transformed S. mansoni schistosomula. 
Schistosomula were treated 3 h post transformation with macaque sera (both heat 
inactivated and not heat inactivated) and their survival rates at 24 h and 48 h post 
treatment were determined. The schistosomula were visualized by brightfield microscopy 
and the viability was assessed by schistosomula integrity with propidium iodide (PI) 
staining [37]. Macaque infection sera at week 14 and week 22 caused patent agglutination 
of schistosomula quickly after contact, while week 0 and week 4 sera did not lead to any 
agglutination. Additionally, we observed a clear time point-dependent effect on gross 
morphology: schistosomula treated with infection sera at week 0 and week 4 resemble 
control schistosomula without serum addition after 24 h of incubation (Fig. 4A). Incubation 
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with sera taken at weeks 8, 14 and 22 caused irregularity of schistosomula surfaces after 
24 h of incubation, which became even more pronounced after 48 h, with blebbing of 
the surface. Similarly, there was an infection time point-dependent relationship with PI 
positivity, where sera at later infection time points caused most schistosomula death as 
measured by PI positivity (Fig. 4B). While 3 h transformed schistosomula treated with sera 
at week 0 resulted in 95% schistosomula survival, week 22 sera reduced survival to 57% 
after 48 h of incubation. 
Immunofluorescence microscopy has confirmed binding of macaque serum 
antibodies at late infection time points to the whole surface of schistosomula at 24 h 
and 48 h post in vitro transformation (Fig. S3). Complement factors did not play a role in 
schistosomula killing as heat-inactivated macaque sera did not lead to increased survival 
of schistosomula compared to untreated sera taken at the same time point, even though 
we still observed patent agglutination and blebbing of schistosomula treated with week 
8, week 14 and week 22 heat-inactivated serum (Fig. S2). 
Glycans with IgGhighand IgMlow binding at week 22 have 
multiple fucosylated LDN motifs 
Rhesus macaques are protected against a secondary schistosome infection 21 weeks after 
primary infection [13]. We observed that serum from macaques infected for 22 weeks had 
Figure 4.  In vitro schistosomula incubation with S. japonicum-infected rhesus macaque sera 
collected at different infection time points. Macaque sera were incubated with 3 hour (h) transformed 
schistosomula. Loss of Schistosomula integrity was visualized by PI positivity. A) Gross morphology 
of schistosomula after 24 h and 48 h of incubation with macaque sera. B) Percentage of PI-positive 




superior killing ability on 3 h in vitro transformed schistosomula compared to sera taken 
from earlier infection time points. The glycan array analyses showed that the IgG and 
IgM balance was changed at week 22 post-infection: while most anti-glycan IgMs have 
decreased, many anti-glycan IgG responses remained high. IgG is generally considered as 
the antibody isotype that provides effective protection to infection while IgMs are found 
to block the activity of protective IgGs by preventing effective antibody-dependent cell-
mediated cytotoxicity (ADCC) of schistosomula in vitro [14]. We compared IgG and IgM 
response intensity at week 22 post-infection, to see which glycan fractions would have 
a difference in IgG and IgM responses, hypothesizing that glycan motifs which are IgGhigh 
and IgMlow could be targets of protective immunity. We performed a statistical analysis 
on glycans that had infection-induced antibody binding at week 22 and found 37 glycan 
fractions that had a significant difference in IgG and IgM binding (Fig. 5A). 12 of these 
fractions had higher IgM than IgG (IgGlowIgMhigh), while 25 fractions had higher IgG than 
Figure 5.  Glycan fractions that have statistically different serum IgG and IgM responses at week 
22 post-infection. A) 37 glycan fractions have a significant difference in IgG and IgM binding 
(p<0.05). Represented glycans are marked with Δ. B) The glycan composition and most likely motif 
of representative fractions of IgG dominant and C) IgM dominant groups are depicted.
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IgM (IgGhighIgMlow). We saw that the glycan fractions that were IgGhighIgMlow almost all 
invariably contained a terminal multi-fucosylated LDN motif (Fig. 5B). In contrast, glycans 
of the IgGlowIgMhigh group did not have highly fucosylated LDN structures and contained 
mostly LeX or LDN-F terminating motifs instead (Fig. 5C). Five fractions were selected to 
represent each group (Fig. 5B and Fig. 5C). Notably, 56% of the glycans in the IgG dominant 
group were cercarial O-glycans (Table S4).
Discussion
Using a microarray approach, we have followed the anti-glycan IgG and IgM responses in 
S. japonicum-infected rhesus macaques over a time course of 22 weeks, from the time of 
infection until the macaques have been reported to become resistant to reinfection while 
eliminating existing worms [13]. The schistosome array used in this study consisted of 
large repertoire of N-, O- and GSL derived glycans isolated from S. mansoni larvae, adult 
worms and eggs [19, 23]. A similar array has previously been used to study the different 
anti-glycan responses in adults and children in S. mansoni endemic regions [19, 23] and 
to study antibodies from local lymph node cells during S. japonicum infection of rats [24]. 
This array has been complemented with a previously established focused synthetic array 
[35] in order to address the antigenic properties of a specific set of xylosyl and fucosyl 
N-glycan core modifications. 
One question addressed in the current study was whether anti-glycan antibodies 
may be associated with the elimination of mature worms by S. japonicum-infected rhesus 
macaques. Previous studies have indicated  that O-glycan expression in schistosome adult 
worms is limited in comparison to cercariae and eggs, and that  antibodies against worm 
glycans are not very cross-reactive with the highly antigenic egg and cercarial glycans 
[23]. In line with this observation, we saw minimal antibodies against worm glycoprotein 
glycans. We have observed that the extent of glycan fucosylation is an important factor 
for triggering the host immune response. Unlike cercariae and eggs that express many 
different antigenic highly fucosylated glycans on both glycoprotein and glycolipids, adult 
worms express antigenic fucosylated glycans such as F-LDN and F-LDN-F predominantly 
on glycolipids [26, 27] and the less antigenic LDN-F and LeX motifs on specific worm N- 
and O-glycan subsets [44, 45].
The glycolipid associated F-LDN and F-LDN-F antigen can be found in undefined 
parenchymal spots or ducts inside the adult worm [26], though the exact function of these 
parenchymal spots and ducts is not understood. Notably, Schistosoma worms isolated 
from 22 week-infected rhesus macaques have diminished body lengths and reproductive 




by macaque IgG attacking gut digestive enzymes, tegument surface hydrolases and 
antioxidant enzymes, eventually leading to worm death through cessation of blood 
feeding [12]. Recently, Li et al. have shown that rhesus IgG binds to the esophageal lumen 
of S. japonicum worms and co-localizes with esophageal secreted proteins, MEGs 4.1, 8.2, 
9, 11 and VAL-7 [16]. It was suggested that rhesus IgGs block esophageal function making 
blood difficult to ingest, which eventually leads to the starvation of schistosome worms. It is 
not known whether glycans are the targets of these IgGs. Interestingly, esophageal located 
protein MEG-4.1 from S. mansoni was found to be heavily O-glycosylated [46] and MEGs 
4.1 and 8.2 of S. japonicum are predicted to have similar properties [16]. It is noteworthy 
that three transcripts of glycosyltransferases were highly enriched in the male esophageal 
region but not in the posterior containing gut and tegument epithelia [47], which might 
indicate the synthesis of novel esophageal glycans. Unfortunately, esophageal located 
MEG proteins are expressed and secreted in minute amounts, and their O-glycans are not 
yet identified. If the esophageal MEG proteins carry unique O-glycans, it is unlikely that 
these are represented on the array due to their very low relative abundance in the overall 
worm glycome. Alternatively, MEGs may contain simple mono- and disaccharides such 
as GalNAc or Galβ1-3GalNAc (T and Tn antigens) that form multivalent O-glycosylated 
peptide domains. Monosaccharides and disaccharides are not isolated and printed using 
our glycan array methodology. If feasible, it would be more appropriate to determine 
binding of antibodies to short O-glycans structured in mucin domains in the context the 
native O-glycopeptide, or an identical synthetic construct thereof.
 As well as eliminating adult worms, rhesus macaques are also found to be resistant 
towards secondary infection 16 weeks or more after primary exposure to schistosomes 
[13]. Freshly transformed schistosomula in vitro representing ‘skin stage’ schistosomula in 
vivo have previously been used to study mechanisms that might be related to reinfection 
[14, 15, 48]. Schistosomula are also susceptible to antibody-mediated damage [8, 49, 50] 
and may the best stage for the immune system to attack the parasite. Schistosomula-
expressed glycans are a subset of glycans expressed by cercaria [27, 40]. We have shown 
that 3 h transformed schistosomula are killed by macaque sera in an infection time point-
dependent manner: sera taken from macaques after 22 weeks of infection were more 
effective at killing than earlier infection time points, suggesting that the macaques may 
build up immunity towards the parasite during the infection. Luyai et al. have previously 
shown that rhesus sera from week 8 and week 11 post-infection were most efficient in 
killing schistosomula of S. mansoni in vitro [22]. However, we observed that macaque sera 
taken 14 and 22 weeks post-infection were even more effective in killing schistosomula 
compared to sera taken 8 weeks after infection.  
At week 14 and week 22, the most prominent epitopes with high IgG binding were 
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the highly fucosylated glycan motifs expressed on O-glycans and glycosphingolipid-
derived glycans. Our statistical analysis on serum IgG and IgM balance at week 22 post-
infection showed that glycans that were statistically IgGhighIgMlow were mostly cercarial 
O-glycan fractions. Moreover, these IgGhighIgMlow cercarial O-glycan fractions all contained 
highly fucosylated LDN epitopes. IgG is usually considered the protective antibody 
isotype compared to IgM. Early studies on human resistance to schistosome reinfection 
found a positive correlation between reinfection intensity and anti-schistosomula and 
anti-egg IgM antibodies [51, 52]. In addition, a strong inverse relationship is observed 
between the rapidity and intensity of IgG response and worm burden at 18 weeks in 
rhesus macaques [12]. We acknowledge that high IgG titers towards a certain glycan 
epitope do not necessarily lead to resistance to reinfection. Different IgG subtypes 
have been shown to vary in their potency in inducing eosinophil-mediated killing of 
schistosomula: human serum IgG1 and IgG3 have been found to be more potent isotypes 
to induce eosinophil-mediated cytotoxicity, whereas IgG4 antibodies are found to inhibit 
the cytotoxicity mediated by IgG1 and IgG3 [15]. IgG2 antibodies are only cytotoxic in the 
presence of activated eosinophils. Additionally, IgG2 and IgG4 were found to correlate 
with susceptibility to schistosome reinfection [52, 53]. Therefore, a protective response 
against skin schistosomula may not simply derive from high titers of a certain antibody 
isotype, but also likely from a balanced selective expression of protective antibodies and 
an absence of blocking antibodies. In our study, glycans in cluster IgG-C3 possessed IgG 
binding 8 weeks post-infection, but these IgG responses disappeared after 14 weeks post-
infection when the macaques are immune to a secondary infection. The glycans in this 
profile were mostly N-glycans with motifs such as LN, LeX, LDN, α2-mannose, terminal 
Gn and terminal fucosylated Gn (Table S1B). We postulate that the disappearance of IgGs 
against these glycan motifs could be involved in the effective immune protection found in 
macaques. On the other hand, it is also intriguing to see that antibodies that are sustained 
after macaque immunity are also found to bind to these motifs. Taking into account the 
different properties of IgG subtypes, it would be relevant to investigate whether the 
IgG response against motifs that disappear during infection clearance are of a different 
subtype than the IgGs that are sustained when macaques are protected. 
At week 22, our last serum collection time point, infected macaques are already 
resistant to secondary infection [10, 16]. We suggest that multi-fucosylated LDN motifs 
that are IgGhighIgMlow may be involved in this resistance. However, Luyai et al. showed 
that macaque sera from week 78 post-infection could not kill freshly transformed 
schistosomula [22]. It would therefore be very interesting to test whether week 78 infected 
rhesus macaques lack the high antibody titers against highly fucosylated LDN epitopes. 




are involved in resistance to reinfection in rhesus macaques or not. Our results using the 
synthetic glycan microarray are in accordance with Luyai et al. [22] that schistosome-
infected macaques generate high IgG antibody responses to the core xylose and core 
α3-core fucose and LeX and LDN epitopes of N-glycans. Nevertheless, it is important to 
realize that core α3-fucose has only been found in mature eggs but not in schistosomula 
of S. mansoni [27] or S. japonicum [28]. Therefore, we believe that antibodies against core 
α3-fucose do not contribute to schistosomula killing. Additionally, unlike the IgG response 
towards multi-fucosylted LDN motifs that is sustained with time, the IgG response towards 
core α3-fucose appears during oviposition and decreases when the adult worm stop 
producing eggs (Fig. 3), further supporting that core α3-fucose is egg-derived. 
Our study of S. japonicum-infected macaques was performed on a S. mansoni-derived 
glycan microarray. On the basis of high similarity in protein coding gene sequences 
between the two species [30] and cross species protein recognition by antibodies [31, 32], 
the glycosylation patterns of the two species are expected to be very similar. Accordingly, 
we observed extensive binding of S. mansoni-derived glycans by serum antibodies from S. 
japonicum-infected rhesus macaques (Fig. 1). Interestingly, although S. japonicum glycans 
were described as less fucosylated than S. mansoni [33, 34], our glycan array data shows 
that antibodies against multi-fucosylated glycans are elicited in S. japonicum-infected 
rhesus macaques, indicating that S. japonicum does produce such glycan antigens, 
including those than contain the Fucα1-2Fucα1- (DF) sequence. 
Rhesus macaques generate a plethora of anti-glycan antibodies during S. japonicum 
infection. In this study, we hypothesized that glycan motifs that have high IgG binding 
could be associated with resistance to Schistosoma infection. It appears that the presence 
of IgG antibodies against multi-fucosylated LDN is correlated with the effectiveness of 
schistosomula killing in vitro. However, it is interesting to see humans that are generally 
susceptible to re-infection also generate antibodies towards many of these fucosylated 
glycans, although to a lower extent [19]. Although this observation certainly does not 
undermine the possible protective effect of anti-glycan antibodies, it indicates that the 
presence of antibodies towards certain epitopes is not directly related to protection. 
As discussed earlier, different studies have shown that antibody isotype balance affects 
resistance to reinfection [15, 51, 52]. Perhaps even in an unprotected infected host, 
protective antibodies exist, but not in sufficient quantities to overcome the infection, 
or protective antibodies are overshadowed by the abundance of irrelevant or blocking 
antibodies. Some researchers have suggested that high antibody responses towards 
glycans are beneficial not for the host, but for the parasite, by directing the immune system 
away from epitopes that could provide protective immunity [18, 29]. Mice vaccinated 
with viable schistosome eggs although eliciting high anti-glycan antibody titers, were not 
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protected against cercarial challenge in vivo [18]. In our case, at least, we have shown that 
high antibody titers against glycans did not prevent rhesus macaques from eliminating 
schistosome adult worms while gaining resistance to reinfection. It is imperative to 
consider that macaques may have intrinsic antibody differences, rather than epitope 
specificity, that lead to protection. Antibody responses towards schistosome glycans 
in S. japonicum-infected rhesus macaques are very dynamic and worth further detailed 
study. Deciphering the specificity of antibodies sustained at week 22 post-infection may 
provide clues to the composition of the antibody pool in a host resistant to schistosome 
re-infection and may provide valuable information about the glycan targets that could be 
involved in protection against re-infection.
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Figure S1. IgG response profile of 
different glycan motifs. Average 
median fluorescence intensities 
are shown for S. japonicum-
infected macaque serum IgG 
over a time course of 22 weeks 
towards different glycan motifs. 
Figure S2. In vitro schistosomula 
incubation with heat inactivated S. 
japonicum-infected macaque sera. In 
vitro schistosomula incubation with heat 
inactivated (HI) S. japonicum-infected 
rhesus macaque sera collected at different 
infection time points. HI Macaque sera 
were incubated with 3 h transformed 
schistosomula. Loss of Schistosomula 
integrity was visualized by PI positivity. A) 
Gross morphology of schistosomula after 
48 h of incubation with HI macaque sera. 
B) Percentage of PI-positive schistosomula 
after 48 h of incubation with HI macaque 
sera at different infection time points.
Figure S3. Binding of S. japonicum-infected macaque serum antibodies to schistosomula. 
Schistosomula were fixed 24 h and 48 h after transformation in 2% PFA. Fixed schistosomula were 
washed twice in 200 μl PBS and then incubated with 0.5 μl of macaque serum (before infection and 
after 22 weeks of infection) in a suspension of 30 μl for 30 minutes. Parasites were washed 1 time 
with PBS and then suspended in 25 μl of 50x diluted rabbit-anti-human IgG, IgM IgA antibodies 
(DAKOPATTS) for 30 minutes. Afterwards, parasites were washed 3 times with PBS and suspended in 
25 μl of 200 x diluted Alexa fluor 488-conjugated goat-anti-rabbit IgG (H+L) antibody (invitrogen) for 
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Figure S4. Binding of monoclonal antibody 128-1E7-C to a collection of  synthetic glycans. 128-1E7-
C is a monoclonal antibody that binds to the Fucα1-3GalNAcβ1,4(fucα1-3)GlcNAc (F-LDN-F)motif 
(Smit et al., 2015). In this figure, the horizontal axis depicts a collection of other glycans that have 
previously been synthesized and described by us (Brzezicka et al., 2015). The same binding assay 
protocol described in the Materials and Methods section was used to detect binding of 128-1E7-C 
to the glycan microarray. 128-1E7-C was incubated at a concentration of 3.5 µg/ml and Alexa fluor 
555-conjugated goat-anti-mouse antibody (Life technologies) diluted 1:1000 was used to detect 
bound monoclonal antibody on the slide.
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Baboons vaccinated with radiation-attenuated cercariae develop high levels of 
protection against schistosome infection, correlating to high antibody titers towards 
schistosome antigens with unknown molecular identity. Using a microarray consisting 
of glycans isolated from different life-stages of schistosomes, we studied the anti-glycan 
immunoglobulin (Ig) G and IgM responses in vaccinated and challenged baboons over 
a time course of 25 weeks. Anti-glycan IgM responses developed early after vaccination, 
but did not rise in response to later vaccinations. In contrast, anti-glycan IgG developed 
more slowly, but was boosted by all five subsequent vaccinations. High IgM and IgG levels 
against O-glycans and glycosphingolipid glycans of cercariae were observed. At the time 
of challenge, while most antibody levels decreased in the absence of vaccination, IgG 
towards a subset of glycans containing multiple-fucosylated motifs remained high until 
6 weeks post-challenge during challenge parasite elimination, suggesting a possible role 
of this IgG in protection. 
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Background
Schistosomiasis is a chronic and potentially deadly parasitic disease that affects millions 
of people in (sub)tropical areas [1-4]. Immunity to Schistosoma species in humans can be 
acquired, but is governed by a complex interplay of factors (e.g. frequency of exposure, 
infections and treatments, and maturation of the immune system) [5-8]. Many efforts have 
been made to develop a vaccine against schistosomiasis but the goal remains elusive. 
So far, vaccination with radiation-attenuated (RA) cercariae has given the highest level 
of protection against infection in several animal models. Optimally attenuated cercariae 
penetrate the skin and enter the bloodstream but fail to mature as the larvae do not travel 
beyond the lungs [9-11]. It is hypothesized that the extended time of interaction between 
parasite and the immune system caused by truncated parasite migration leads to better 
recruitment of lymphocytes and induction of antibodies [10, 12]. Protection induced 
by the RA vaccine is effective in naïve animals, and in those receiving drug treatment or 
chronically infected [13], representing the endemic situation in humans.
Baboons, like humans, are natural hosts for schistosomes [14]. In experimental 
conditions up to 80% of penetrating cercariae can mature into adult worms [15-17]. 
Protection induced by the RA cercarial vaccine correlates with the development of 
parasite specific IgG [15, 18, 19] mostly directed towards the glycan fraction of cercarial 
and egg secretions [20]. Identifying parasite glycans targeted by the host immune system 
is crucial to better understand protective and non-protective anti-glycan responses that 
may be elicited during infection or vaccination. Antigenicity, the dynamics and longevity 
of antibody responses, are relevant in selecting suitable targets for vaccine development. 
Our previous studies showed that when rhesus macaques develop “self-cure” resistance 
against schistosomiasis, they produce an abundance of IgG antibodies against glycans 
containing multiple fucoses [21]. Such highly fucosylated glycan structures are abundant 
in cercariae and eggs, two life stages that share many cross-reactive antigens, but not at the 
surface of adult worms [22]. The resistance to schistosome infection acquired by macaques 
occurs from 12 weeks post-infection [23] by which time the triggers of antibodies to cross-
reactive glycans in cercariae or eggs cannot be distinguished. In contrast, vaccination with 
RA cercariae provides a unique opportunity to investigate anti-glycan responses induced 
by cercariae and early schistosomula antigens alone, without the background of a massive 
anti-egg response. 
In this study, we used a glycan microarray to analyse serum from an earlier baboon 
vaccination study. We investigated the anti-glycan IgG and IgM response over a period of 
25 weeks with the aim of revealing glycan targets possibly involved in protection. The array 
comprises a library of naturally occurring schistosome-derived N-, O- and glycosphingolipid 





Animal experiment ethics statement
All experimental procedures were approved by independent scientific and ethical 
committees at the Institute of Primate Research, Nairobi, Kenya. Sera were from experiment 
1 of a study in which juvenile olive baboons were exposed to 9,000 irradiated cercariae on 
5 occasions at 4-week intervals [18]. Three weeks after the last vaccination, these animals, 
plus a control untreated group, were challenged with 1,000 cercariae. Blood was sampled 
every 2 weeks, from vaccinated animals starting at day 0 and from controls at challenge. 
Materials
Cy3 conjugated goat anti-human IgG (Fc-specific), BSA and ethanolamine were from 
Sigma (Zwijndrecht, the Netherlands). Alexafluor 647 conjugated goat anti-human IgM (µ 
chain specific) was from Invitrogen (Breda, The Netherlands).
Glycan microarray 
Previously generated N-, O- and GSL glycan microarrays were used [24, 25]. Printed array 
slides were incubated with primary sera at 1:100 dilution followed by fluorescently-labeled 
secondary antibodies at 1:1,000 dilution and scanned using a G2565BA scanner (Agilent 
Technologies, Santa Clara, CA). Data and image analysis was performed with GenePix 
Pro 7.0 software (Molecular Devices, Sunnyvale, CA). Background-subtracted median 
intensities were averaged and processed as previously described [24-26].
Hierarchical clustering analysis
Datasets were log2 transformed to remove the basic trends of variance. MultiExperiment 
Viewer v4.5 (https://sourceforge.net/projects/mev-tm4/) was used to perform the 
hierarchical clustering analysis to group associated glycan fractions. Complete linkage 
clustering and Euclidean distance metric were used to perform the clustering analysis. 
The outcome was that glycan fractions inducing similar antibody dynamics were grouped 
into the same cluster profile.
Schistosomula transformation and binding assays
Cercariae were transformed and antibody binding to schistosomula were determined 
using previous protocols [21]. Briefly, cercariae were incubated at 37°C in M199 medium 
supplemented with 1:100 1M HEPES pH7.4, 1x antibiotic antimycotic solution, 1.5 mM 
glutamine and 10% FCS, for 20 min. Schistosomula were then concentrated in the center 
of a petri dish on an orbital shaker, resuspended in the above medium and cultured at 
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37°C in a humidified atmosphere with 5% CO2. 
For binding assays, baboon sera were added at 1:10 dilution to duplicate cultures 
of 250 schistosomula at 3 hours post-transformation. Immediately after treatment, the 
culture plate was observed to detect changes such as agglutination, and again at 72 hours 
to determine the morphological effects of treatment and the induction of schistosomula 
killing [21].
Immunofluorescent microscopy
All steps in the protocol were followed by washing in PBS. Three-hour in vitro transformed 
schistosomula were fixed in 2% paraformaldehyde, then incubated for 30 minutes 
at 37°C with 20 ul 5x diluted baboon serum, Protein G-purified baboon IgG, or IgG-
depleted baboon serum. Antibody binding was detected using at 1:1000 dilution of FITC-
conjugated anti-human IgG and AlexaFluor 647-conjugated anti-human IgM antibodies 
for another 30 minutes at 37°C, followed by transfer to a 96-well plate and analysis by 
fluorescence microscopy (Leica AF_6000). Where pre-incubations were necessary, they 
were also performed at 37°C for 30 minutes.
Results
Vaccination with irradiated cercariae induces IgM and IgG 
responses against various cercarial glycans
We incubated baboon serum with schistosome glycan microarrays to document anti-
glycan antibody responses during sequential vaccinations with irradiated cercariae 
(Figure 1). The IgM response against many glycan targets was detectable by 2 weeks after 
the first vaccination. It peaked at week 6, two weeks after the second vaccination when 
most IgM responses were directed against cercarial O-glycans and GSL glycans. Some 
anti-cercarial glycan responses were cross-reactive with egg-derived N- and O-glycans 
present on the array, although no eggs were present in the animals. Antibodies to N- and 
O-glycans derived from adult worms were not detected over the whole time course, but 
among the GSL glycans several were (co-) expressed by adult worms.
Similar to IgM, cercarial O-glycans and GSL glycans were the main targets of IgG 
antibodies in the vaccinated baboons but with different dynamics. The induction of the 
IgG antibodies towards most glycans occurred more slowly than IgM, taking six weeks and 
two vaccinations to elicit a clear response. Subsequent vaccinations further boosted the 




ratio occurred (Figure 2) as IgG titers against cercarial O- and GSL glycans continued 
to rise, while the IgM titers did not, indicative of a heavy-chain class switch. Both IgM 
and IgG responses towards cercarial O- and GSL glycans followed a sawtooth pattern 
with a peak two weeks after each vaccination. This pattern was especially consistent 
for IgG responses against cercarial GSL derived glycans, requiring regular boosting to 
augment. It is noteworthy that neither IgG nor IgM anti-glycan responses were boosted 
upon challenge infection at week 19 (Figure S1 and S2). The slight increase in antibody 
response of vaccinated animals against cercarial O- and GSL glycans at 25 and 23 weeks, 
respectively, could reflect the few challenge parasites that survived in the vaccinated host. 
Indeed, in challenge control baboons a steep increase in IgM response against cercarial 
GSL and O-glycans was observed at 23 weeks (Figure S2B), similar to that seen in week 4 
vaccinated baboons. 
Figure 1. Averaged serum IgG and IgM responses from RA cercaria-vaccinated baboons to glycans 
isolated from different life stages of schistosomes. The horizontal axis indicates N-, O- and GSL glycan 
fractions from S. mansoni cercariae (Cerc.), adult worms, and eggs. Average background-subtracted 
median fluorescence intensities are shown for IgG and IgM over a time course of 18 weeks. Each bar 
corresponds to antibody binding to individual glycan fractions printed on the glycan microarray. N: 
N-glycans. O: O-glycans and L: glycosphingolipid (GSL) glycans. V: time of vaccination.
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Figure 2. Anti-cercarial-glycan response of RA cercariae vaccinated baboons during vaccination. 
Averaged IgM (open circle) and IgG (closed circle) response towards cercarial O-, GSL and N-glycans 
over the 18 weeks of RA cercariae vaccination. GSL: glycosphingolipid glycans.
IgM and IgG response profiles of baboons vaccinated with 
irradiated cercariae
To better understand the antigenicity of specific cercarial glycan motifs, we performed a 
hierarchical clustering analysis of the IgM and IgG response patterns, thereby grouping 
cercarial glycans with similar antigenicity profiles. Anti-glycan antibody responses were 
corrected for baseline (week 0) intensity. Four IgM response profiles, IgM-C1, IgM-C2, IgM-C3 
and IgM-C4, were identified (Figure 3A). IgM-C1 and IgM-C2 followed similar patterns, 
both reaching their maximum at 6 weeks and remaining relatively stable thereafter, with 
IgM-C1 containing more potent targets than IgM-C2 (Figure 3B). Substantial changes only 
occurred in IgM-C1 and IgM-C2 after challenge, where a decline was observed at week 
23. The IgM-C1 cluster contained mainly cercarial O-glycans while those in IgM-C3 and 
IgM-C4 were mostly N- and GSL derived (Figure 3C). The multiple-fucosylated-LDN motif 
was mainly present in IgM-C1 (Figure 3D), while the Gn motif containing more than one 
fucose was highly abundant in IgM-C2 but not IgM-C1. 
The extent of fucosylation on the Gal-LDN motif expressed on O-glycans did not 
appear to affect its antigenicity. Four IgG response profiles, IgG-C1, IgG-C2, IgG-C3 and 
IgG-C4 were also identified (Figure 4A). IgG-C1 contained highly antigenic glycans: IgG 
against this cluster reached a high titer at 10 weeks post-vaccination with only minor 
fluctuations thereafter (Figure 4B). Glycans in IgG-C1 bound most antibody and it was 
the only cluster to which a sustained response was observed at week 19 after cercarial 
challenge. IgG against glycans in IgG-C2 rose quickly in the first 4 weeks, similar to IgG-C1. 
Each booster vaccination increased IgG binding to the IgG-C2 glycans, although overall 
it was lower than to IgG-C1, and unlike in IgG-C1, the IgG response towards glycans in 
IgG-C2 decreased after week 19. The glycans in both IgG-C3 and IgG-C4 showed very 
low binding. IgG-C4, the least antigenic cluster of glycans, was dominated by cercarial 
N-glycans (Figure 4C), while those in IgG-C1 and IgG-C2 were mostly derived from 




Figure 3. Hierarchical clustering analysis of anti-cercarial glycan IgM response in baboon serum 
during vaccination and challenge infection. A) Hierarchical cluster of anti-glycan IgM response 
dynamics. The reduction in antibody binding compared to week 0 is indicated in blue, while the 
increase is indicated in red. Glycan fractions inducing similar antibody dynamics are grouped into 
the same cluster profile. B) Response profile curve for each major IgM cluster. C) Distribution of IgM 
cluster profiles based on glycan origin. D) Percentage distribution of cluster profiles assigned in A) 
to various glycan motifs. O: O-glycans; GSL: glycosphingolipid glycans; N: N-glycans. 
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Figure 4. Hierarchical clustering analysis of anti-cercarial glycan IgG response in baboon serum 
during vaccination and challenge infection. A) Hierarchical cluster of anti-glycan IgG response 
dynamics. The reduction in antibody binding compared to week 0 is indicated in blue, while the 
increase is indicated in red. Glycan fractions inducing similar antibody dynamics are grouped into 
the same cluster profile. B) Response profile curve for each major IgG cluster. C) Distribution of IgG 
cluster profiles based on glycan origin. D) Percentage distribution of cluster profiles assigned in A) 




motifs containing e.g. Fucα1-3GalNAcβ1-4(Fucα1-3)GlcNAc- or Fucα1-2Fucα1-3GlcNAc- 
elements were more abundant in IgG-C1 and IgG-C2 (Figure 4D). Structures with no/low 
fucose content were more abundant in IgG-C3 and IgG-C4. 
Binding of serum IgM and IgG of vaccinated baboons to in 
vitro transformed schistosomula
After identifying antigenic glycan targets of antibodies induced by protective vaccination 
of baboons, we examined whether the serum would recognize antigens present on the 
surface of schistosomula, as binding is essential for the action of antibody dependent 
cellular mechanisms. We found that both IgM and IgG bound to the surface of 3 hour 
transformed schistosomula fixed in 2% paraformaldehyde (Figure 5A); the binding 
patterns were in accordance with the presence of anti-glycan IgM and IgG measured by 
glycan microarray. At week 6 post-vaccination, IgM bound to the surface of schistosomula 
with high intensity, whereas IgG binding was higher in week 19, correlating with the IgG 
titers against cercarial O- and GSL glycans shown in figure 2A. In control baboons, upon 
challenge infection at week 19, IgM and IgG binding to the surface of schistosomula was 
negative, but by week 25, strong IgM and weak IgG binding to the surface of schistosomula 
was observed, similar to that seen 6 weeks after vaccination. 
Figure 5. Serum antibody binding to the surface of 3 hour transformed schistosomula. A) anti-
human IgM (red) and anti-human IgG (green) antibodies were used to detect vaccinated and 
challenge control baboon serum IgM and IgG binding on the surface of schistosomula fixed in 2% 
PFA. B) Agglutination of live schistosomula after 24 hours incubation with baboon sera. 
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In addition, we also found that vaccinated baboon sera taken at 6 weeks to 19 weeks, 
as well as week 25 control baboon serum were able to agglutinate live schistosomula 
in vitro (Figure 5B). This agglutination of was not caused by the IgG fraction, as protein 
G-purified serum IgG did not cause agglutination (Figure S3A), suggesting that other 
serum components, such as IgM, were responsible. Additionally, IgG-depleted serum 
from week 6 post-vaccination was able to agglutinate schistosomula more effectively 
than week 19 vaccination sera, corresponding to the higher IgM titers at week 6, further 
indicating a role for IgM in the agglutination.
Lastly, since both IgM and IgG bound to the surface of schistosomula, we tested if the 
presence of one isotype would prevent the binding of the other. In a series of antibody 
competition experiments, schistosomula were pre-incubated with either purified IgG 
or IgG-depleted sera before analyzing the binding of IgM and IgG. We found that IgG-
depleted sera from week 6, containing high titers of IgM, did not prevent purified IgG 
binding to the surface of the parasite (Figure S3B). Likewise, pre-incubating with the 
purified IgG fraction from week 19 vaccinated serum, containing high titers of IgG, did not 
prevent IgM binding to the surface of schistosomula (Figure S3C). 
Discussion
In this study we have explored the glycan-directed antibody response in serum from 
baboons given protective vaccinations with RA S. mansoni cercariae and found that 
IgM and IgG target highly antigenic glycan structures with multifucosylated GalNAc/
GlcNAc motifs. Despite recognizing similar antigenic glycan motifs, only IgG titers were 
boosted after successive vaccinations, while IgM responses reached a plateau after two 
vaccinations or decreased to baseline thereafter. Multi-fucosylated glycan motifs are 
expressed throughout the development of schistosomes, from cercariae to adult worms 
and eggs, although in different contexts on N-, O- and GSL glycans [22]. As a cercaria 
transforms into a schistosomulum, it loses its glycocalyx with highly fucosylated glycan 
motifs on O-glycans, which remains in the epidermis. Thereafter, the schistosomulum 
still expresses multi-fucosylated glycan motifs on its surface more likely linked to lipids 
than proteins. Although antigenic O-glycans may no longer be exposed on the surface 
of 3 day-old schistosomula or on juvenile worms, the glycocalyx residues in the skin may 
continue to serve as an antigen source eliciting antibodies that can cross react with GSL 
glycans [22, 27, 28].
The site and mechanism of challenge parasite elimination in hosts protected by 




antibody-dependent cellular mechanisms in vitro by a combination of murine antibodies 
and macrophages [29, 30] but in vivo evidence is tenuous [29, 30]. Indeed, the developing 
resistance of maturing schistosomula in killing assays has been attributed to the loss 
or masking of surface antigens. Thus ex vivo isolated lung schistosomula show minimal 
surface antigenicity when incubated with chronically infected or RA cercaria-vaccinated 
mouse sera [31], and there is no direct evidence for antibody-mediated killing of lung-
stage schistosomula. Surprisingly, therefore, parasite tracking studies have revealed that 
challenge elimination in RA vaccinated mice occurs at the lung stage of migration [32]. 
Indeed, some passive immunization experiments in mice have shown that RA cercariae 
vaccinated mouse serum is most successful when given around 5 days post challenge, 
when the larvae are in the lungs, rather than at the time of challenge [33, 34], and IgG was 
the crucial component [34, 35]. The lack of evidence for direct killing led to the proposal 
that lung-stage schistosomula fail to mature because their intravascular pulmonary 
migration is blocked by inflammation mediated by activated macrophages [36, 37]. The 
situation in the vaccinated baboon is unclear because the site and timing of challenge 
parasite elimination is unknown, which makes evaluation of the potential role of glycans 
in the process difficult.
Nevertheless, we have previously shown that in vitro-transformed S. mansoni cercariae 
still express highly antigenic multi-fucosylated glycan motifs on the schistosomula surface 
up to one week post-transformation [28], and may thus serve as targets for direct immune 
attack or initiators of pulmonary inflammation. Any discrepancy could be explained 
by the faster development of schistosomula in vivo compared to in vitro transformed 
counterparts, so losing (or masking) fucose binding sites earlier. To conclude whether the 
antibodies elicited against multi-fucosylated motifs in RA cercaria-vaccinated baboons can 
target lung-stage schistosomula would require direct isolation of the parasite developing 
in the vaccinated baboon.
The lack of information on the site of challenge elimination in baboons leaves open 
the possibility that skin-stage schistosomula might be the target of immune attack in that 
host. We found that baboon vaccination serum containing high titers of anti-glycan IgG 
and IgM bound to the surface of 3-hour schistosomula in vitro, indicating the abundance 
of antigenic targets for interaction with immune effector cells. Unfortunately, due to the 
limitation of serum, we were unable to purify anti-glycan antibodies to confirm their 
specific contribution, and whether they could mediate antibody-dependent cellular 
cytotoxicity. In addition to parasite binding, we observed that the IgG-depleted fraction 
of baboon serum with high anti-glycan IgM titers was able to agglutinate schistosomula, 
most likely due to the pentameric IgM structure cross-linking multiple targets. Assuming 
that IgM was the agglutinating agent and its targets were glycans, then the targets are 
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most likely lipid-associated because agglutination levels decreased with time in parallel 
with IgM responses to GSL glycans. We suggest that IgM against GSL glycans is an unlikely 
participant in protection due to its low titer at week 19 after multiple vaccinations. 
Furthermore, considering the large size (990kDa) of IgM, it is unlikely to readily leave the 
bloodstream for the skin tissues [38]. As a result, GSL glycans abundant on the newly 
transformed schistosomula at the skin stage will remain inaccessible to IgM until they 
enter the bloodstream about four days after skin penetration. 
In several vaccination or resistant primate models, there is a positive correlation with 
IgG and negative correlation with IgM in relation to protection [15, 18, 21, 39]. Serum 
IgM has been demonstrated to act as a blocking antibody, preventing cytotoxic attack 
on schistosomula in vitro by effector IgG antibodies [40]. We consistently saw that IgM 
responses rose rapidly in response to vaccination and challenge, but this increase was 
short-lived. Ten weeks after vaccination appeared to be the turning point where IgM:IgG 
ratios changed, with subsequent vaccinations boosting only IgG titers. At the point 
of challenge, the IgG response against cercarial O- and GSL glycans was at its highest, 
consistent with the possibility that anti-glycan IgG is important in protection. We have 
shown in vitro via antibody competition experiments that the presence of IgM does not 
prevent IgG from binding to the surface of schistosomula, but based on our glycan array 
data, there was no indication that IgM and IgG recognized different glycan targets. This 
further emphasises that the IgM/IgG balance is relevant in a protection profile, where 
high IgG titers are essential for protection. Thus the presence of protective IgG could 
mediate cellular mechanisms necessary for protection in vaccinated baboons. It is worth 
noting that when schistosomula are grown to the blood-feeding stage in vitro in the 
presence of S. mansoni-infected ‘self-cure’ rhesus macaque serum (versus naïve macaque 
serum), their growth is inhibited [23]. In addition, incubating 3-hour in vitro transformed 
schistosomula with serum from rhesus macaques resistant to secondary infection caused 
schistosomula death [21]. In contrast, incubating baboon serum with schistosomula in 
similar experiments did not cause any observed damage (data not shown), suggesting 
that the involvement of immune cells is necessary for baboon immunity.
Mature schistosome eggs are a potent source of highly antigenic glycans but 
vaccination with viable schistosome eggs does not elicit protection in different animal 
models [20], despite generating high titers of anti-glycan antibodies that react with 
penetrating schistosomula [41-43]. This observation led to the smokescreen hypothesis 
suggesting that antigenic glycans deflect the immune response away from critical and 
susceptible protein epitopes [44]. However, multiple studies have also shown that the 
presence of eggs does not prevent the host from developing protection. Thus, previous 




vaccination in baboons [13] and resistance to reinfection occurs after eggs are produced 
by mature worms in the rhesus macaque self-cure model [21]. In an experimental setting 
where vaccinated baboons were previously infected with schistosomes, the overwhelming 
response to parasite egg deposition makes it difficult to discern a contribution from 
vaccination [13]. The current study protocol gave us the unique opportunity to study 
anti-glycan responses in the context of protection induced solely by anti-larval immune 
responses; it confirmed that many larval glycan epitopes are shared with eggs. It is worth 
noting that each female worm deposits around 300 eggs per day in the blood vessels of 
the gut wall. Thus a patent infection of around 500 worm pairs in a baboon results in a 
diurnal production of 150,000 eggs, equivalent to the biomass of five vaccinations with 
9000 attenuated cercaria [45]. Given that RA cercaria vaccination can induce protection 
in infected baboons [13], perhaps the anti-cercarial antibody response may be in some 
important way different from those induced by eggs. It would be valuable to perform 
additional experimental immunizations in animal models with cercarial and egg-derived 
antigen preparations, as well as with defined glycans, to unravel what those differences 
are. 
In this study we analyzed the anti-glycan antibody responses elicited against specific 
glycan motifs during RA cercaria-vaccination in baboons which eventually developed 
resistance to challenge infection. IgG against highly antigenic motifs such as multi-
fucosylated glycan epitopes were developed at high titers, similar to those previously 
seen in the ‘self-cure’ rhesus macaque model. It is notable that the generation of these 
anti-multi-fucose antibodies does not require the presence of eggs. Nevertheless, multiple 
vaccinations were necessary to boost the titers of IgG, which resulted in better protection 
against challenge infection. Such antibodies against highly fucosylated glycans are 
also generated in humans susceptible to schistosome infections [24]. Future studies to 
establish the role of antibodies against multi-fucosylated glycan motifs require active 
vaccination experiments with glycoconjugates containing these glycan epitopes.
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Figure S1. Averaged serum IgM and IgG response from RA cercaria vaccinated and challenge control 
baboons to glycans isolated from different life stages of schistosomes. The horizontal axis indicates 
N-, O- and GSL glycan fractions from schistosome cercariae (Cerc.), adult worms, and eggs. Average 
background-subtracted median fluorescence intensities are shown for IgM and IgG after challenge 
infection at week 19. Each bar corresponds to antibody binding to individual glycan fractions 
printed on the glycan microarray. N: N-glycans. O: O-glycans and L: glycosphingolipid (GSL) glycans. 
C: Challenge infection with live cercaria.
Figure S2. Anti-schistosome glycan response of RA cercaria vaccinated and unvaccinated challenge 
control baboons after challenge infection. IgG (closed circle) and IgM (open circle) response towards 
glycan antigens isolated from different lifestages of schistosomes in serum isolated from RA cercaria 
vaccinated (A) and unvaccinated challenge control (B) baboons. Cerc N: cercaria derived N- glycan. 
Cerc O: cercaria derived O- glycan. Worm N: worm derived N- glycan. Worm O: worm derived O- 
glycan. Egg N: egg derived N- glycan. Egg O: Egg derived O- glycan. Cerc GSL: cercaria derived 
glycosphingolipid linked glycan.
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Figure S3. A) Agglutination of live schistosomula in vitro by whole serum, purified serum IgG  and 
IgG depleted serum from vaccinated baboons at week 6 and week 19. B) Serum IgM (red) and IgG 
(green) binding to schistosomula after pre-incubation with IgG depleted serum. The presence of 
IgM in the pre-incubation did not prevent IgG binding to the surface of schistosomula. C) Serum 
IgM (red) and IgG (green) binding to schistosomula after pre-incubation with purified IgG of week 
19 vaccinated baboon serum. Week 19 vaccinated baboon serum contained high amounts of IgG. 
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Infection with schistosomes is accompanied by the induction of antibodies against the 
parasite. Despite high serum IgG titers against both protein and glycan antigens, infected 
individuals remain infected until treated and re-infection is common in endemic areas. 
Parasite specific IgG subclasses may differ in functionality and effectivity with respect 
to effector functions that contribute to parasite killing and immunity. In this study, we 
investigated if specific IgG subclass responses target specific antigenic schistosome 
glycan motifs during human infection. Sera from 41 S. mansoni infected individuals from 
an endemic area in Uganda were incubated on two glycan microarrays, one consisting of 
a large repertoire of schistosome glycoprotein- and glycolipid- derived glycans and the 
other consisting of chemically synthesized core xylosylated and fucosylated N-glycans 
also expressed by schistosomes. Our results show that highly antigenic glycan motifs, such 
as multi-fucosylated terminal GalNAc(β1-4)GlcNAc (LDN) can be recognized by all IgG 
subclasses of infection sera, however with highly variable intensities.  Detailed analysis of 
N-glycan core modifications revealed individual antibody responses specific against core-
xylosylated and core α3-fucosylated motifs that are life stage specifically expressed by 
schistosomes. IgG1 and IgG3 were detected against a range of N-glycan core structures, 
but IgG2 and IgG4, when present, were specific for the core α3-fucose and xylose motifs 
that were previously found to be IgE targets in schistosomiasis, and in allergies. This study 
is the first to address IgG subclass responses to defined helminth glycans.
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Introduction
Schistosomiasis is a parasitic infection of humans and mammals contracted by exposure 
to schistosome cercariae shed by infected aquatic snails. Once the parasite establishes 
itself in a human host, the infection which is associated with debilitating pathology due 
to tissue-deposition of eggs remains chronic until treated. In the schistosomiasis endemic 
areas in Africa, South-America and South-East Asia, reinfection after treatment is common. 
Longitudinal studies have shown that resistance to re-infection with schistosomes 
develops very slowly. Many years of exposure to schistosomes and multiple treatments 
are required for the immune response to become effective [1-3]. Various studies have 
shown that anti-schistosome antibodies are pivotal for anti-parasite immunity. Passive 
immunization with serum or monoclonal antibodies against schistosome antigens [4-7] 
were shown to reduce worm burden and egg production in previously unexposed mice 
upon challenge with schistosomes. Moreover, transfer of sera and of purified IgG from 
animals immunized with the protective Sm-p80 antigen conferred resistance to challenge 
infection, and it has been shown that the level of protection induced by immunization 
with Sm-p80 is reduced in antibody deficient mice [8]. 
As schistosomes are highly glycosylated organisms that express many glycan 
motifs different from mammals, it is not surprising that an abundance of antibodies 
are generated against schistosomal protein- and lipid-linked glycans exposed to the 
host [9-14]. It is becoming increasingly clear that glycan antigens play an important 
role in helminth infection immunology, but it remains ambiguous whether anti-glycan 
antibodies contribute positively or negatively to protection. 
Previously we have studied the anti-glycan IgG and IgM responses in schistosome 
infected rhesus macaques that are able to expel the worms [15], in order to identify 
glycan targets of antibodies that might be involved in the self-cure mechanism. We 
showed that serum IgG antibodies against highly fucosylated schistosome glycoproteins 
and glycolipids formed during infection were sustained when the macaques cleared 
the infection, indicating that these antibodies are present in a protective context and 
possibly play a role in the killing of adult worms in the host. Additionally, sera from 
macaques containing high titers of IgG against highly fucosylated motifs were able to kill 
schistosomula in vitro. [15] and it has been shown that a monoclonal antibody specific 
for the fucosylated LeX antigen was protective in a mouse model of S. mansoni infection 
[6]. On the other hand, humans that are generally susceptible to reinfection also have 
high titers of IgG antibodies against highly fucosylated motifs [16], indicating that anti-
glycan antibodies are not necessarily protective. Indeed, some studies have regarded 




attacking vulnerable peptide epitopes that could mediate protective responses [17-19]. It 
has however been appreciated that protective glycan epitopes may also occur, but these 
could be under-represented and masked by irrelevant or ‘smokescreen’ epitopes [20]. As 
a consequence, protective anti-schistosome glycan responses may be difficult to identify. 
These observations called for investigations into differential recognition of specific 
schistosome glycan motifs in different models and cohorts such as reported in several 
recent glycan microarray-assisted studies [12-16, 21].
Alternatively, research into the IgG subclass-specific response towards defined 
glycan antigens may shed light on the role of anti-glycan antibodies in infection. 
Perhaps the key to associate glycan antigens with immunity is not in the antigen itself, 
but rather by the type of antibody response generated. Particular IgG subclasses have 
been found to correlate with resistance or susceptibility to schistosome infection: IgG1 
against schistosome surface antigens were observed in putatively resistant individuals 
in a Brazilian cohort [22], while individuals that were chronically infected lacked high 
IgG1 against the same antigens, but mounted high IgG4 towards various schistosome 
antigens instead. IgG4, as well as IgG2 have been found to correlate with susceptibility 
of schistosome reinfection [23, 24]. On the other hand, human serum IgG1 and IgG3, as 
well as IgE have been found to be potent inducers of eosinophil-mediated cytotoxicity, 
while IgG4 antibodies were found to be inhibiting cytotoxicity [25] and compete with IgE 
to prevent antigen cross-linking and IgE mediated effector function [26]. So far, studies 
on IgG subclass response against schistosome antigens have focused on schistosome 
surface proteins [22] or complex ill-defined schistosome antigen mixtures such as SEA or 
AWA [27]. Little is known however, about IgG subclass reactivity to defined schistosome 
glycan antigens. Interestingly, a recent study has shown that anti-glycan IgE responses 
are highly restricted towards only a few specific epitopes out of the many glycan antigens 
expressed by schistosomes, in particular N-glycan core-xylose or core α3-fucose, motifs 
that are often associated with plant glycans and allergens [28]. 
In the current study, we address the question whether specific serum IgG subclass 
responses to defined antigenic glycans occur during human schistosome infection, and 
whether these might be restricted to certain motifs or not. To this end, we tested the IgG 
subclass responses in a selection of 41 serum samples from a relatively homogeneous 
population in terms of exposure and infection intensity [16, 29] towards a large collection 
of schistosome glycan antigens. Using two glycan microarrays, one comprising a large 
set of native glycans isolated from different schistosome life-stages [14-16], the other 
comprising a set of synthetic N-glycans with different core and branch modifications 
previously described [21] we determined for each of the IgG subclasses which glycan 
motifs are targeted during infection, and evaluated whether these are different or not for 
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IgG1-4. Our results indicate that in schistosomiasis sera, each of the IgG subclasses can be 
directed against a variety of antigenic glycan motifs, but with different patterns for the 
different individuals tested. To our knowledge, this is the first study that addresses IgG 
subclass responses to defined glycans and glycan motifs in a helminth infection.
Material and Methods
Sera
Sera used in this study were described in an earlier publication [16] where 41 schistosome 
infected individuals were selected from an original cohort study in a highly prevalent 
S. mansoni endemic area [29]. The cohort study obtained ethical approval from the 
Uganda National Council for Science and Technology (UNCST) and was supported by the 
Cambridge Local Research Ethics Committee. Selected subjects had an age range of 5 to 
46 years old, all with patent S. mansoni infection. The geometric mean of the intensity of 
infection measured by egg per gram (epg) feces was 560.65 (CI 95%: 343.88, 914.05).
Glycan microarray construction and incubation
A glycan microarray constructed of glycans derived from S. mansoni cercariae (75 N-glycan 
fractions and 102 O-glycan fractions), adult worms (77 N-glycan fractions and 31 O-glycan 
fractions) and eggs (57 egg N-glycan fractions and 98 soluble egg antigen O-glycan 
fractions), and 30 glycans derived from glycosphingolipids representing multiple life 
stage, was described previously [14, 16]. 24 blank spots with spot buffer were included 
for array background control. Each glycan fraction was immobilized on a glass slide in 
triplicate. The synthetic glycan microarray containing a collection of core-xylosylated and 
core-α3 and -α6 fucosylated N-glycans with various core extensions has been described 
previously [21].
Binding assays of individual or pooled sera on both arrays were conducted following 
the protocol as described previously [14-16]. Briefly, the microarray slide was blocked with 
2% BSA, 50 mM ethanolamine in PBS. Serum samples were diluted 1:100 in PBS-0.01% 
Tween20 with 1% BSA. All four mouse anti-human isotype antibodies were purchased 
from Invitrogen. IgG1 and IgG3 were labelled with the Promokine PF-647 labelling kit; 
IgG2 and IgG4 were labelled with the PF-555 labelling kit following the manufacturer’s 
protocol. All anti-human IgG subclass antibodies were diluted 1:200 in PBS-0.01 Tween20 
to detect bound serum antibodies on the slide. All washing steps were performed with 
successive rinses with PBS-0.05% Tween20 and with PBS. The last washing step was 
finished by an additional wash with milliQ water and the slides were dried and kept in the 




Scanning and data analysis
A G2565BA scanner (Agilent Technologies, Santa Clara, CA) was used to scan the slides 
for fluorescence at 10 um resolution using lasers at 532 nm and 633 nm. Anti-IgG2 and 
anti-IgG4 antibodies were detected at 532 nm and anti-IgG1 and anti-IgG3 antibodies at 
633 nm. Data and image analysis was performed with GenePix Pro 7.0 software (Molecular 
Devices, Sunnyvale, CA). Spots were aligned and re-sized using round features with no CPI 
threshold. Background-subtracted median intensities were averaged per time point and 
processed as described by Oyelaran et al. [30]. Datasets were log2 transformed to remove 
the basic trends of variance. A hierarchical clustering analysis (HCA, complete linkage 
clustering using Euclidean distance metric) was performed to group associated glycan 
fractions using MultiExperiment Viewer v4.5. 
Results
Serum IgG subclass response against glycans expressed by 
schistosomes in infected individuals
To investigate whether IgG subclasses in sera from a schistosome-infected cohort react 
with specific motifs or subsets of parasite-associated glycans, we determined IgG1, 
IgG2, IgG3 and IgG4 binding intensities against a large variety of glycans in pooled sera 
of 41 infected individuals using glycan microarrays. These sera were from a relatively 
homogeneous population in terms of exposure and infection intensity. All individuals had 
patent S. mansoni infection (geometric mean infection intensity (epg) was 560.65 (CI 95%: 
343.88, 914.05)). We found that in the pool IgG of all four subclasses are present against a 
wide range of schistosome-derived N-, O- and glycosphingolipid glycans printed on the 
array (Fig. 1A). IgG1 and IgG2 bound to the various glycans with similar high intensities, 
while anti-glycan IgG4 binding intensities were lowest out of the four subclasses. Glycan 
targets for each of the IgG subclasses consisted mainly of highly fucosylated LDN epitopes, 
abundantly expressed on glycolipid-derived glycans and cercarial O-glycans [31]. 
Interestingly, IgG subclass binding of N-glycan core xylose (abundant on glycans from 
cercariae and miracidia) and core α3-fucose epitopes (abundant on glycans from eggs 
and miracidia), as determined by use of the synthetic glycan array, were rather different 
across the four subclasses (Fig. 1B). 
IgG1, IgG3 and IgG4 in pooled infection serum showed higher binding intensities 
to core α3-fucose containing structures than to structures containing only core xylose, 
with IgG4 being restricted to different subsets of the α3-fucose containing structures. In 
contrast, IgG2 response in this pool was mainly directed towards core xylose containing 
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N-glycans. Core α3-fucose has been shown to be an antigenic target in schistosome-infected 
humans, mice and rhesus macaques[12, 15]. Interestingly, alone or in combination with core 
xylose, core α3-fucose also forms the major cross-reactive carbohydrate epitopes that are IgE 
targets on a variety of plant-derived allergens [28, 32, 33].  To further analyze the differential 
reaction of specific IgG subclasses with core-modified N-glycans, we investigated the IgG 
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Figure 1. Schistosome infected individuals produce IgG subclass antibodies to schistosome glycans. 
Averaged serum IgG subclass response from schistosome-infected individuals to A) complex N-, 
O- and glycosphingolipid glycans isolated from different life stages of schistosomes and B) core 
modified N-glycans synthesized chemically. The horizontal axis indicates different glycan structures. 
Each bar corresponds to antibody binding to individual glycan fractions printed on the glycan 
microarray. Schistosome GSL glycans are shown as a group irrespective of the life stage. N: N-glycans. 




Schistosome infected individuals differentially express IgG 
subclass antibodies towards schistosome glycans
Among the individual sera incubated on the synthetic glycan array a striking variability 
in IgG subclass response towards the core-modified glycans was observed (Fig. S1). Most 
sera contained antibodies binding to core α3-fucose and core xylose modified N-glycans. 
However, this was not a universal response and no clear correlation between IgG subclass 
and glycan motifs was observed.
IgG subclass response profile of schistosome infected 
individuals 
In view of the variations in IgG subclass responses to the core-modified N-glycans 
between individuals, we performed a hierarchical clustering analysis and grouped the 
individuals based on response patterns for each IgG subclass (Fig. 2A). We observed a 
cluster of individuals that had specific and high IgG1, 2, 3, or 4 binding to core α3-fucose 
(cluster red). Another cluster of individuals had high IgG binding to core xylose containing 
structures (cluster blue), while the third cluster, with the highest number of individuals, 
only had lower amounts of IgG binding to either core α3-fucose or core xylose (cluster 
yellow). When comparing the IgG subclass distribution for each motif within each 
serum, we saw that some individuals had high binding to core α3-fucose with all four 
IgG subclasses (cluster red in all subclasses) (Fig. 2B), while other individuals responded 
strongly to core α3-fucose structures with only one or two subclasses that were variably of 
the IgG1, 2, 3, or 4 type. Similarly, two individuals of the 41 individuals responded strongly 
to core xylose containing N-glycans with all IgG subclasses (cluster blue in all subclasses), 
while other individuals responded only with one or two subclasses, variably of the IgG2, 
IgG3 or IgG4 class. These observations indicate that IgG subclass responses towards these 
glycan antigens are not restricted by the nature of the antigen, but rather appear to be 
related to each individual response to the infection. One interesting observation was that 
most of the individuals that had high IgG subclass response towards either core xylose or 
core α3-fucose were children aged twelve or younger (Fig. 2B).  
Structural motifs bound by IgG1 – 4
Next, to gain more insight in the structural determinants that are recognized specifically 
by the different IgG subclasses, we examined in detail how the binding of IgG1, IgG2, 
IgG3 and IgG4 to core α3-fucose and core xylose is influenced by adjacent structural 
elements. Comparison of the signal intensities of four sets of structurally related synthetic 
glycan structures first revealed that moderate levels of IgG1 and IgG3 reactive with the 
unsubstituted trimannosyl core glycan (Man3GlcNAc2) (G42) were detected in most sera 
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tested (Fig. 3A-C). In contrast, IgG2 and IgG4 to the N-glycan core were only detected 















Figure 2. Hierarchical clustering analysis of anti-glycan antibody responses in schistosome 
infected individuals. A) Heatmap showing IgG subclass response of schistosome infected subjects 
(columns) to core modified N-glycan fractions (rows) that have been synthesized and described by 
Brzezicka et al.. Median fluorescence intensity was corrected for baseline and log2 transformed; 
increase in antibody binding is indicated by the red color intensity. Three major clusters of subjects 
were identified for each IgG subclass based on antibody binding intensity to glycans: one cluster 
of individuals had high IgG binding to core α3-fucose (red), another cluster of individuals to core 
xylose (blue) and one cluster of individuals without specific binding to core α3-fucose or core 
xylose (yellow). Core xylosylated and core α-3 fucosylated structures are indicated. Within core-
xylose containing structures, those that have additional monosaccharides on the α-3mannose (Δ) 
and those that miss the core α-6mannose (*) are indicated. B) IgG subclass response profile of each 
schistosome infected individual. Red: high response against core α3-fucose; blue: high response 
against core xylose; yellow: low response against other glycans. Filled circles: age 12 and under. 




Interestingly, IgG1 and IgG3 in general did not become more reactive upon addition 
of core xylose to the trimannosyl core, but signal intensities did increase significantly upon 
α3-fucosylation while core α6-fucose addition (G64) had the opposite effect of lowering 
the IgG1 and IgG3 response to the otherwise unsubstituted trimannosyl core (Fig. 3A, C). 
The addition of α6-fucose had no effect on the reactivity of any of the four IgG subclasses 
to the α3-fucosylated core however (G64) (Fig. 3C). Regarding the combination of both the 
antigenic core xylose and core α3-fucose modifications it appears that sera where IgG2 
and IgG4 reactivity is negative against core α3-fucose becomes positive upon addition 
of the xylose (G37) (Fig. 3D). Since reactivity is also observed to core-xylosylated glycans 
without fucose, it appears that α3-fucose and xylose form independent antigenic motifs. 
Finally, IgG2 and IgG4, but not IgG1 and IgG3 reactivity against core xylose are hindered 
by the addition of a GlcNAc branch to the 3-linked Man (G5), but removal of the 3-linked 






































































































































































A) B) C) D)
G42 G64  G73  G75G42    G34    G5 G42  G34  G2  G1 G73    G37    G39
Figure 3. IgG subclass response of schistosome infected individuals to core xylose (A and B) and core 
α3 fucose (C and D) in the presence or absence of adjacent structural elements. Median fluorescence 
intensity was corrected for baseline and log2 transformed. The code for each structure as described 
in the original publication [21] is indicated.
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accessibility (Fig. 3A, B). Together these data suggested that IgG2 and IgG4 reactivity to 
N-glycan core structures in schistosomiasis sera are either against the core xylose and core 
α3-fucose motifs, whereas IgG1 and IgG3 are less specific and restricted. 
Discussion
In this study we have investigated the IgG subclass responses against defined parasite-
derived glycans in schistosome-infected individuals. Detailed glycan microarray analysis 
indicated that IgG1, 2, 3 and 4 in schistosome infection sera are variably present against 
a wide range of antigenic parasite glycans. Interestingly, individuals infected with 
schistosomes respond with particularly high variability to the antigenic α3-fucose and 
β2-xylose core modifications of N-glycans with respect to the different IgG subclasses. 
This variability in antibody response was not a reflection of the intensity of infection as 
all sera included this study were from heavily infected individuals living in a schistosome 
endemic area. The sera used in this study were selected from a larger study [29], where 
selected individuals had an age range between 5 to 46 years old, all with patent S. mansoni 
infection, with fecal egg counts between 343.88 and 914.05 epg (CI95% of geometric 
mean). Previously, we have used this set of sera to compare the anti-glycan (total) IgG and 
IgM in schistosome infected children and adults [16] and found that although there were 
anti-glycan antibody differences between children and adults, other factors apart from 
age also played a role in shaping anti-glycan antibody response profiles. It is well known 
that the overall serum IgG subclass distribution is generally different between adults and 
children. IgG1 and IgG3 development is faster and reaches around 75% of the adult serum 
levels at the age of five, while IgG2 and IgG4 levels rise much slower, reaching 70% of 
adult serum levels at the age of 14. Nevertheless, large inter-individual variations were 
observed previously for IgG subclass development [34], as corroborated by our study. 
Although most individuals with responses of any subclass towards core modified glycans 
were children, many children did not produce antibodies against core modified N-glycans, 
raising the question which other factors, possibly cross-reactive antigens, determine the 
induction of these schistosome-reactive antibodies.
The sample selection used here to study the glycan specificity of IgG subclasses in 
schistosomiasis infection serum is not suitable for addressing immunoepidemiological 
questions. Nonetheless, the variable subclass responses to specific glycan antigens 
observed in this study may have the potential to reflect the immune profile of infected 
individuals and act as markers for infection with respect to intensity, exposure, chronicity, 




schistosome tegument protein antigens for instance have been observed in putatively 
resistant individuals in a Brazilian cohort but not in chronically infected individuals, where 
high IgG4 antibodies against the same schistosome antigens were observed instead [22]. 
In addition, IgG1 and IgG3 against protective schistosome antigens has also been found 
in naturally resistant individuals but not in chronically infected or unexposed individuals 
[35]. These studies indicate the importance of IgG1 against protective antigens in 
developing immunity. In contrast, susceptibility to reinfection in humans has been 
associated with high levels of IgM, IgG2 and IgG4 [23, 24, 26, 27]. The presence of IgM, IgG2 
and IgG4, purified from serum of infected individuals, prevented eosinophil mediated 
killing of schistosomula by other IgG subclasses present in human infection sera [25]. 
The IgG4 subclass is usually produced after repeated, long-term antigenic stimulation, 
and has minimal effector functions. Literature describes highly elevated IgG4 towards 
schistosome antigens [26] that may compete with IgE and prevent antigen cross-linking 
and IgE mediated effector functions. Interestingly, although we have not observed very 
high IgG4 binding intensities against schistosome glycans, precisely the core α3-fucose 
and core xylose motifs that form the cross-reactive carbohydrate determinants for IgE in 
plant allergens as well as helminths [28, 33, 36] are also the only IgG4 reactive glycan 
elements in the tested N-glycans in the current study. It should be noted that expression 
of core α3-fucose and core xylose motifs during the schistosome life cycles appears to be 
highly specific. By mass spectrometric glycomics approaches it has been shown that core 
xylose is abundant on N-glycans of cercariae and miracidia [31], whereas core α3-fucose 
has been detected in abundance in N-glycans on the secretory egg glycoproteins IPSE/
α1 [37] and omega-1 (together with core α6-fucose) [38] and on N-glycans derived from 
the miracidia  [31] and the egg glycoprotein kappa-5 (together with α6-fucose and core 
xylose) [39]. Both core xylose and core α3-fucose are expressed by plant glycoproteins [33, 
40] and in a small subset of other helminths [36]. The specific IgG determined in our study 
may therefore also have been triggered by other antigen sources other than schistosomes. 
It would be interesting to investigate the IgG subclass response of infected 
individuals towards more complex glycan antigens that are schistosome specific, such as 
highly fucosylated LDN epitopes on glycoproteins and glycosphingolipids of the parasite 
and its secretions. Such complex schistosome antigens, induce higher total IgG binding in 
schistosome infected rhesus macaques compared to core modified epitopes [15]. Given 
that highly fucosylated motif such as Fucα1-2Fucα1-3 on LDN have not been found in 
organisms other than schistosomes, it would be interesting to see if different individuals 
would have a less variable IgG subclass distribution to these complex, more parasite-
specific glycan antigens, when these would become available as synthetic, defined 
antigens. 
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In this study we have for the first time investigated the IgG subclass response against 
schistosome glycans in infected individuals. The complex interplay between how antigens 
trigger IgG subclass response calls for analysis with a larger human cohort with better 
defined resistant and susceptible immune profiles, to be able to understand whether 
particular subclasses against particular glycan epitopes are associated with a disease state. 
Although high inter-individual antibody variation was observed against core modified 
N-glycans expressed by schistosomes, IgG subclass response against complex antennae 
schistosome glycans remain to be elucidated.
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Figure S1. Different schistosome infected  individuals respond to glycans with different IgG 
subclasses. Heatmap showing IgG subclass response of schistosome infected subjects (columns) to 
core modified N-glycan fractions (rows) that have been synthesized and described by Brzezicka et al.. 
The position order of each individual along the vertical axis is the same for all four subclasses. Antibody 
median fluorescence intensity was corrected for baseline and log2 transformed; increase in antibody 
binding is indicated by the red color intensity. Core xylosylated and core α-3 fucosylated structures 
are indicated. Within core xylosylated structures, those that have additional monosaccharides on the 
α-3 mannose (Δ) and those that miss the core α-6 mannose ( ) are indicated.
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Figure S2. Averaged serum IgG subclass responses from S. japonicum-infected rhesus macaques 
to synthetic core modified N-glycan fractions. The horizontal axis depicts core modified N-glycan 
fractions that have been synthesized and described by Brzezicka et al.. Average median fluorescence 
intensities are shown for S. japonicum-infected macaque serum IgG over a time course of 22 weeks. 
Each peak along the vertical axis corresponds to each individual glycan fraction printed on the 
glycan microarray. Core xylosylated and core α3-fucosylated structures are indicated.  
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In the past decades, a substantial number of schistosome proteins have been evaluated as 
vaccine candidates in rodent models. However, glycan vaccine targets have remained so far 
unexplored. In this study, rats were immunized with neoglycoproteins Fucα1-3GlcNAcβ1-
BSA (FGn-BSA) and Fucα1-2Fucα1-3GlcNAcβ1-BSA (FFGn-BSA) to mimic multi-fucosylated 
schistosome glycans previously suggested to be associated with protection against 
schistosomes in non-human primate models. Immunizing rats with FGn-BSA significantly 
reduced liver worm burden upon S. mansoni challenge infection by 38% and 29% in 
two independent experiments compared to control rats immunized with unconjugated 
BSA. Rats immunized with FGn-BSA not only generated specific antibodies towards the 
fucosyl motif of glycoconjugates FGn-BSA and FFGn-BSA, antibodies elicited by FGn-BSA 
immunization also bound to native glycans isolated from different schistosome life stages, 
mainly against lipid-derived glycans containing terminal Fucα1-3HexNAc motifs (HexNAc 
= GalNAc, GlcNAc). Although the mechanism of protection is not clear, we show that FGn-
BSA immunized rat serum IgG and IgM antibodies bound to the entire surface of 3 hour 
transformed schistosomula, confirming the presence of target glycan epitopes on the 
schistosomulum. This indicates that antibody-dependent mechanisms may be involved 
in immunity against developing larvae upon challenge infection, which accounts for the 
protection seen in FGn-BSA immunized rats.
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Introduction
Schistosomiasis is a debilitating parasitic disease resulting in high levels of morbidity in 
areas where schistosome infections are endemic and chronic. Treatment with Praziquantel 
(PZQ), the only anti-schistosomal drug available, does not prevent reinfection, which 
limits the success of mass drug administration programs [1]. Moreover, extensive use of 
PZQ may lead to the emergence of drug-resistant schistosomes, similar to what happened 
during extensive use of drugs against veterinary helminths [2-5]. Considerable efforts are 
therefore dedicated to finding and designing an effective therapeutic and/or prophylactic 
vaccine against schistosomiasis. 
Antigens suitable for forming the basis of a vaccine in principle are all immunogenic 
molecules accessible to the host immune system that can trigger a protective cellular or 
humoral immune response [6]. For Schistosoma mansoni, multiple protein antigens have 
been explored as vaccine targets, mainly in rodent models, but so far only Sm-TSP-2, 
rSm14/GLA-SE, and Sm-p80 advanced into clinical development [7-9]. It is well known 
that in addition to protein antigens, schistosomes express a plethora of antigenic and 
non-antigenic glycans, mostly conjugated to protein or lipid carriers. Glycans expressed 
throughout the schistosome life cycle, some life stage-specific, others occurring in all life 
stages, play an important role in the parasite biology as well as in host-parasite interactions 
[10, 11]. For example, glycans on egg glycoproteins and -lipids activate innate immune 
responses and modulate immune cell function in various in vitro and in vivo systems 
[12-14], and cercarial secretions have been shown to trigger alternatively activated 
macrophages via glycans [15, 16]. Moreover, strong anti-glycan antibody responses are 
induced in schistosome-infected hosts. In particular to secreted and cell-surface expressed 
glycoproteins, anti-glycan antibody levels are high compared to anti-protein antibodies 
[17-22]. The relevance of antibodies against schistosome glycans during infection is a 
subject of debate. Mice vaccinated with schistosome eggs elicit high titers of anti-glycan 
antibodies, but this vaccination does not lead to protection [17, 23-25]. On the other hand, 
in animals resistant to schistosome infection after vaccination with irradiated cercariae 
[26] or in semi-permissive rhesus macaques which ‘self-cure’ after patent infection, high 
anti-glycan antibody responses were also observed [27]. These observations raise the 
question if specific schistosome glycan antigens may be applicable for the development 
of alternative anti-schistosome vaccine candidates.
Fucosylated glycan antigens containing Fucα1-3GlcNAc and Fucα1-2Fucα1-3GlcNAc 
elements are expressed by S. mansoni throughout the lifecycle, with the latter element 
displaying a unique Fucα1-2Fuc glycosidic linkage, so far only found in Schistosoma 




of fucosylated glycans are not only elevated during schistosome infection but are also 
highly abundant in the context of immunity against schistosomes generated by irradiated 
cercariae vaccination in baboons [26] and by a primary infection in self-curing macaques 
[27]. 
To study the possible contribution of anti-fucose antibodies in protective immunity 
against schistosome infection more directly, we applied a rodent vaccination model 
utilizing synthetic glycan epitopes. As small glycans alone are not successfully processed 
and presented by antigen presenting cells to trigger an effective antibody response, 
affinity maturation and IgG class switching [29, 30], multivalent BSA conjugates of 
fucosylated di- and trisaccharides were constructed [31]. Rats were immunized with these 
neoglycoproteins with unconjugated BSA as control, and worm burden after challenge 
infection with S. mansoni cercariae was assessed as end-point read out for the protective 
effect of immunization. In contrast to humans and mice which are fully permissive, rats are 
semi-permissive hosts for S. mansoni that eliminate most of the parasites around 4 weeks 
post infection [32-34]. Each early pre-clinical in vivo model for schistosome vaccination 
has its specific limitations and advantage. Although being semi-permissive to S. mansoni 
infection, the rat shares critical decisive humoral effector mechanisms, such as effector cells 
involved in antibody-dependent cellular-cytotoxicity, and antibody isotype regulatory 
mechanisms with the human hosts that lack in mice [35]. In particular for prophylactic 
vaccination, targeting larval and juvenile worms in the skin and lung stage before full 
maturation, the rat may be a useful experimental vaccination model. 
Here we show that immunization with a synthetic Fucα1-3GlcNAcβ1-BSA-conjugate 
induced IgG and IgM against fucosylated schistosome glycans present on schistosomula 
and significantly reduced worm burden upon S. mansoni challenge. 
Materials and methods
Animals and parasites
Seven-week-old Fischer male rats were purchased from Charles River. A Guadeloupean 
strain of S. mansoni used was maintained in Biomphalaria glabrata snails and golden 
hamsters as intermediate and definitive hosts, respectively [36].
Synthesis of glycoconjugates and characterization
The synthesis of fuco-oligosaccharides used for rat immunization has been previously 
described [31]. Synthetic carbohydrates Fucα1-3GlcNAcβ1-(CH2)6-NH2 (FGn) and Fucα1-
2Fucα1-3GlcNAcβ1-(CH2)6-NH2 (FFGn) were conjugated to BSA using diethyl squarate 
chemistry as described by van Roon et al. [31], creating multivalent neo-glycoproteins 
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(FGn)n-BSA and (FFGn)n-BSA with n = 10-12, further denoted FGn-BSA and FFGn-BSA, 
respectively. Unfucosylated Gn-BSA [31] was used in this study as a control for anti-Fucose 
serum IgG and IgM in ELISA.
Immunization schedule and challenge
Rats were immunized with 50 µg of FGn-BSA, FFGn-BSA and BSA via sub-cutaneous 
injection with complete Freund’s adjuvant. Two boosts with 30 µg of glycoconjugates 
were injected 3 weeks and 5 weeks later i.p. in incomplete Freund’s adjuvant. Two weeks 
after the last injection, (7 post-vaccination) rats were first bled and then percutaneously 
infected with 2000 S. mansoni cercariae as described by Smithers and Terry [37]. FGn-BSA 
immunization was repeated in a second experiment with the same vaccination scheme, 
except that 60 µg of glycoconjugate was used in the primary immunization. The method 
of injection, boosting and adjuvant remained the same as the first experiment.
Blood collection and worm burden analysis
Blood was collected from rats before immunization at week 0 (prebleed), before 
infection at week 7 and upon sacrifice at week 10.  At three weeks post infection, rats 
were euthanized and Schistosoma worms were recovered by perfusion. In each case the 
protection level was calculated by comparing the recovered total worm number from 
each glycoconjugate group in relation to the control group immunized with BSA. 
ELISA
An ELISA was used to detect specific antibodies produced by glycoconjugate-vaccinated 
rats. Maxisorb Nunc immunoplate (Sigma-Aldrich) were coated overnight with 1 µg/
ml of FGn-BSA, FFGn-BSA, Gn-BSA or BSA diluted in pH 9.6 carbonate buffer at 4°C, and 
blocked with 0.1% Tween diluted in PBS for 1 hr at 37°C. Rat sera collected at 7 weeks 
post vaccination were pooled for each group and applied as serial dilution starting at 
1:200 dilution in 0.05% Tween in PBS; 50 µL rat vaccination sera was applied per well and 
incubated for 1 hr at 37°C. After washing, the plates were incubated for 1 hr with 10,000x 
diluted biotinylated goat-anti-rat-IgG (Abcam) and goat anti-rat IgM (Abcam) detection 
antibody, followed by 10,000x diluted streptavidin-HRP in 0.05% Tween in PBS for 30 
minutes at 37°C.  50 µL of TMB was used for detection and the reaction was stopped by 50 
µL 1.8 M H2SO4 and absorbance was measured at 450 nm.
Glycan microarray
We have previously described the generation and application of microarrays consisting 
of N-, O- and glycosphingolipid (GSL) glycans isolated from different life stages of S. 




sera from 7 weeks post vaccination at 1:100 dilution followed by fluorescently labeled 
secondary antibodies at 1:1,000 dilution and scanned using a G2565BA scanner (Agilent 
Technologies, Santa Clara, CA). Data and image analysis were performed with GenePix 
Pro 7.0 software (Molecular Devices, Sunnyvale, CA). Background-subtracted median 
intensities were averaged and processed as previously described [18, 38, 39]. 
The structures of a selection of glycan targets printed on the microarray recognized 
by antibodies in FGn-BSA immunization sera were characterized in detail by MALDI-TOF 
MS/MS fragmentation as described previously [38]. 
Schistosomula transformation 
Cercariae were transformed to schistosomula as previously described [27]. Briefly, cercariae 
were incubated at 37°C in M199 medium (Gibco), supplemented with 1:100 1 M HEPES at 
pH7.4, 1x antibiotic antimycotic solution (ABAM), 1.5 mM glutamine and 10% fetal calf 
serum for 20 minutes and transferred to a petri dish. Using orbital shaking, schistosomula 
were concentrated in the center of the petri dish, collected and cultured in the above-
mentioned medium for 3 hours.
Immunofluorescent binding assays
Schistosomula collected after the 3 hour incubation period were fixed in 2% 
paraformaldehyde and incubated with 5x diluted rat vaccination sera for 30 minutes at 
37°C. IgG and IgM binding was detected using 1:250 dilution of AlexaFluor 488-conjugated 
anti-rat IgG and AlexaFluor 647-conjugated anti-rat IgM antibodies for another 30 minutes 
at 37°C. All steps in the protocol were followed by washing in PBS. Immunofluorescence 
was analyzed with fluorescence microscopy (Leica AF_6000). 
Results
Vaccination with FGn-BSA and FFGn-BSA in rats reduced 
worm burden after challenge infection
Various types of fucosylated glycans expressed by schistosomes have previously been 
found to be a target of IgM and IgG in schistosome-infected hosts [18, 21, 26, 27]. To 
investigate whether responses to these types of antigens may be protective, we performed 
vaccination experiments in rats with glycoconjugates containing representative 
fucosylated glycan motifs. Three groups of 8 rats received either FGn-BSA, FFGn-BSA or 
BSA control in Freund’s adjuvant. Three immunizations were given through i.p. injection at 
week 0, week 3 and week 5 (Figure 1A). At week 7, rats were infected with 2000 cercariae. 
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Three weeks later rats were perfused to recover worms and worm burden was 
determined. The mean worm count in FGn-BSA immunized rats was 149 worms, while 
in the control group immunized with BSA on average 237 worms were recovered, 
Figure 1. Rat immunization schedule and worm burden following challenge infection in 
glycoconjugate immunized rats. A) Rats were immunized 3 times with BSA, FGn-BSA, or FFGn-BSA 
at week 0, week 3 and week 5. In rat immunization I, 50 µg was used in the first injection while 60 
µg was used in rat immunization II. At week 7, rats were infected with 2000 S. mansoni cercariae 
percutaneously. Liver perfusion and worm recovery were performed at week 10 when the rats were 
sacrificed. Blood was sampled at week 0, week 7 and at week 10. B) Worm burden of glycoconjugate 
immunized rats 3 weeks post challenge infection. 





corresponding to a 38% decrease in worm burden (p<0.01) in the FGn-BSA immunized 
group compared with control rats (Figure 1B and Table 1). FFGn-BSA vaccinated rats had a 
14% decrease in worm burden, but this reduction was not significant, and the spread was 
large (sem: 34.9). The protection induced by FGn-BSA immunization in rats was confirmed 
in a second experiment where we observed a decrease of 29% in worm burden in FGn-
BSA vaccinated rats compared with control rats immunized with BSA only (Table 1 and 
Figure 1C). 
Anti-glycan antibodies induced by  FGn-BSA and FFGn-BSA 
immunization
To characterize antibody responses triggered by glycoconjugate immunizations, we 
measured serum IgM and IgG at week 7 against  FGn-BSA and FFGn-BSA, and the Gn-
BSA and BSA controls, using ELISA (Figure 2). Rats immunized with FGn-BSA and FFGn-
BSA glycoconjugates develop higher IgM response towards the FGn-BSA and FFGn-BSA 
antigen compared to Gn-BSA and BSA, indicating that antibodies against the fucosyl 
motifs were induced (Figure 2A). Interestingly, IgM levels against FGn-BSA and FFGn-BSA 
were similar in FGn-BSA and FFGn-BSA immunized rats, suggesting that a significant cross-
reactivity between these antigenic motifs exists. A lower, but clearly detectable reactivity 
to Gn-BSA by IgM in the sera of FGn-BSA or FFGn-BSA immunized rats was observed, 
indicative of BSA and/or Gn-linker directed antibodies. Mice immunized with BSA alone 
also develop an elevated IgM response towards the FFGn-BSA and FGn-BSA conjugates 
compared to prebleed. 
Figure 2. Serum antibody response of immunized rats to defined glycan antigens. BSA, FGn-BSA 
or FFGn-BSA immunized rat serum were collected 7 weeks post immunization before challenge 
infection. Serum IgM (A) and IgG (B) antibody response towards BSA controls, FGn-BSA, FFGn-
BSA  and Gn-BSA were measured by ELISA. Prebleed: pooled rat control serum collected prior to 
immunization.
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The anti-BSA response of BSA immunized rats was lower however than that elicited 
by FGn-BSA and FFGn-BSA immunized rats, indicating that the presence of fucosylated 
glycans stimulated the IgM response to BSA. In contrast, IgG responses against BSA where 
equally high in both BSA immunized and BSA-glycoconjugate immunized rats (Figure 
2B). Furthermore, IgG in FGn-BSA and FFGn-BSA immunized rats bound to Gn-BSA with 
similar intensity as to the matching immunogen. These observations suggest that the IgG 
detected by the ELISA are mainly directed against the carrier protein BSA.
Next, to find out whether the rat antibodies induced by FGn-BSA and FFGn-BSA 
vaccination also bound to native schistosome glycans, we performed a schistosome 
glycan microarray analysis of pooled rat vaccination sera collected at week 7, just before 
schistosome infection (Figure 3). We found that the FGn-BSA-immunized rats developed 
IgM that bound to a range of naturally occurring schistosome glycans, most intensely to 
many glycosphingolipid (GSL)-derived glycans. IgG from FGn-BSA immunized rats bound 
almost exclusively to GSL-derived glycans on the microarray. Surprisingly, week 7 pre-
challenge serum of FFGn-BSA immunized rats on the other hand, did not contain IgM 
nor IgG significantly recognizing the numerous naturally occurring schistosome glycans 
present on the microarray. 
Figure 3. Averaged serum IgM and IgG response from glycoconjugate vaccinated rat sera collected 
7 weeks post immunization to glycans isolated from different life stages of schistosomes. The 
average median fluorescence intensities are shown for FGn-BSA and FFGn-BSA immunized rats 
after subtraction with that of BSA-immunized rats. Each bar corresponds to antibody binding to 
individual glycan fractions printed on the glycan microarray. N: N-glycans. O: O-glycans and GSL: 
glycosphingolipid glycans. *: Glycan fractions described in figure 5.
Whilst FGn-BSA immunization elicited antibodies towards a specific subset of 
schistosome glycans on the microarray, challenge infection by exposure of immunized 




antigens (Figure 4). At 3 weeks post challenge infection, high IgM levels were measured 
against a wide range of cercarial N- and O-glycans, GSL-derived glycans isolated of 
different life stages, and egg-derived N- and O-glycans.  As no eggs are produced during 
schistosome infection in rats, the antibody reactivity towards egg glycans is due to cross-
reactivity with a subset of cercarial glycans that contain identical antigenic motifs to eggs 
[11, 27].  Moreover, anti-glycan IgM and IgG responses mounted upon challenge were 
in general stronger in FGn-BSA immunized rats than in BSA or FFGn-BSA immunized 
rats. Compared to IgM, IgG raised following challenge infection was more selective and 
directed towards a narrower subset of glycan targets.
Figure 4. Averaged serum IgM and IgG response from glycoconjugate vaccinated rat sera collected 
3 weeks post challenge infection to glycans isolated from different life stages of schistosomes. The 
average median fluorescence intensities are shown for BSA, FGn-BSA and FFGn-BSA immunized 
rats. Each bar corresponds to antibody binding to individual glycan fractions printed on the glycan 
microarray. N: N-glycans. O: O-glycans and GSL: glycosphingolipid glycans. 
Hypothesizing that antibodies binding to fucosylated glycans of the schistosome 
are responsible for the observed protection induced by FGn-BSA immunization, we 
further investigated which native glycan motifs are recognized by FGn-BSA antisera. 
MALDI-TOF MS fragmentation analysis was applied to multiple glycan fractions positive 
for IgM and IgG binding (Figure 5). These MS analyses indicated that glycan antigens 
recognized by FGn-BSA rat immunization serum all contained Fucα1-3HexNAc motifs 
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(HexNAc=GalNAc, GlcNAc), presumably as part of the terminal Fucα1-3GalNAc(Fucα1-
3GlcNAcβ1-) tetrasaccharide antigen (F-LDN-F) which is abundant in schistosome glycans 
[11]. In contrast, to glycans with non-fucosylated terminal GalNAc/GlcNAc residues or with 
fucosylation at non-terminal positions in the glycan backbone, no binding was observed. 
Antisera of glycoconjugate immunized rats bind to the 
surface of schistosomula 3 h after transformation 
After identifying glycans with terminal Fucα1-3HexNAc motifs as antibody targets in 
FGn-immunized rats, we examined whether the corresponding serum would recognize 
such antigens present on the surface of schistosomula. Both IgM and IgG of FGn-BSA 
immunized rat antisera bound to the surface of 3 hour (h)  transformed schistosomula 
(Figure 6). FFGn-BSA immunized and BSA immunized rat serum did not show antibody 
Figure 5. MALDI-TOF MS fragmentation analysis of glycan fractions recognized by serum IgM and 
IgG of FGN-BSA immunized rats. Representative glycan fractions that had positive binding with 
FGn-BSA immunized rat antisera are depicted (Egg lipid fraction NP14-RP03 and NP22-RP04); These 
glycans contained terminal Fucα1-3HexNAc motifs. Glycans lacking terminally fucosylated HexNac 




binding to the parasite. This is in accordance with the patterns seen in the glycan microarray 
analysis where only FGn-BSA immunized rats produce antibodies to native schistosome 
glycans. The presence of antigenic targets on the surface of the parasite recognized by 
FGn-BSA immunization sera indicates that upon challenge infection antibody-dependent 
mechanisms are potentially involved in immunity against developing larvae and 
subsequent reduction of worm burden after challenge in the FGn-BSA immunized group.
Figure 6. Rat antisera binding to the surface of schistosomula 3 h after transformation. Anti-rat IgM 
(red) and anti-rat IgG (green) antibodies were used to detect serum IgM and IgG binding on the 
surface of schistosomula fixed in 2% PFA. 
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Discussion
In schistosomiasis, antibodies directed to many glycan antigens seem to be unprotective, 
or perhaps even counter protective by inhibiting immunity or stimulating evasive 
mechanisms [17]. However, similar to anti-protein antibodies, a subset of anti-glycan 
antibodies may relate to protection. We here report for the first time that immunization 
with an antigenic glycan expressed by schistosomes reduces worm burden after 
challenge infection with S. mansoni. In two separate experiments, vaccination of rats with 
the neoglycoprotein FGn-BSA, a multivalent presentation of the Fucα1-3GlcNAc motif, 
significantly limited worm burden by 38% and 29%, respectively. 
Vaccination with the α3-fucosylated FGn-BSA conjugate induced IgM, and to a lesser 
extent IgG, antibodies against a wide range of schistosome glycans containing fucosylated 
motifs as determined by glycan microarray analysis (Figure 3). In addition, FGn-BSA 
immunization serum IgG and IgM was found to bind to targets over the entire surface of 
schistosomula 3 hours after transformation (Figure 6), confirming the presence of target 
glycan epitopes on the schistosomulum surface. Fucosylated glycans are highly abundant 
on cercariae and schistosomula as shown previously in monoclonal antibody based IFA 
studies [10]. The current microarray data (Figure 3) suggest that FGn-BSA immune serum 
IgG binds primarily to GSL glycans. These GSL glycans with fucosylated LDN-motifs have 
been established to be exposed on the surface of schistosomula for up to two weeks after 
transformation after they lose their glycocalyx [10]. 
The serum antibody binding profile of partially protected FGn-BSA immunized rats 
was very similar to that seen in vaccinated baboons protected from challenge infection 
[26] and serum from macaques that are resistant against reinfection [27]. This strongly 
suggests that anti-fucosylated glycan antibody responses in macaques and vaccinated 
baboons also contributed to the protective immune response in these hosts. Previously, we 
were not able to directly identify the specific antibody targets associated with protection 
due to the complexity of the responses induced by irradiated cercariae or full infections. 
However, in this study we showed that protected rats vaccinated with FGn-BSA developed 
antibodies that recognized naturally occurring schistosome lipid derived glycans with a 
fucosylated terminal N-acetylhexosamine. GSL glycans with terminal non-fucosylated 
N-acetylhexosamine were not bound, despite having fucosylated N-acetylglucosamines in 
the backbone stretch. This further supports the hypothesis that the protective antibodies 
generated by FGn-BSA vaccination in rats have a specificity for α3-fucosylated terminal 
N-acetylhexosamines on schistosome GSL glycans. 
In addition to generating fucose specific IgG and IgM antibodies, we observed that 




glycans 3 weeks post challenge, when compared to BSA or FFGn-BSA immunized rats. 
These elevated anti-glycan antibody levels were not specific to certain glycan epitopes 
only, but FGn-BSA immunization seems to have sensitized the rats to many glycan 
antigens exposed after the cercarial challenge. Perhaps the elevated antibody response 
could account for a recall response that prepares the host to resist parasite infection. 
Previous studies have shown that effective immunity in the radiation attenuated 
vaccine model involved a mixed Th1/Th2 immune responses [40, 41], which is why both 
complete and incomplete Freund’s adjuvant were used during vaccination in rats. Perhaps 
a balanced Th1 and Th2 response is necessary for protection against S. mansoni infection. 
However, Freund’s adjuvant cannot be used in humans. On the other hand, Alum, a 
Th2 response inducer which is considered the safest adjuvant for human vaccines [42, 
43], could be useful for extrapolating results. Alternatively, the synthetic TLR4 agonist 
glucopyranosyl lipid adjuvant formulated in a squalene-in-water emulsion (GLA-SE), a 
strong Th1 inducer [44] with the ability to increase extrafollicular antibody response and 
long-lived antibody production [45] that has proved to be a safe and potent clinical stage 
adjuvant [46], could also be considered to test efficacy under Th1 inducing conditions.
In this study, antibodies against schistosome GSL glycans appear to be crucial 
for protection. It is known that GSL glycans express highly fucosylated epitopes [11] 
including terminal Fucα1-3, as well as Fucα1-2Fucα1-3 disaccharide. Interestingly, 
immunization with FGn-BSA, but not FFGn-BSA  appeared to be effective in inducing a 
protective response. Despite binding to the FFGn-BSA glycoconjugate, serum antibodies 
of FFGn-BSA immunized rats did not bind to naturally occurring schistosome glycans, 
indicating that this conjugate fails to induce antibodies that react with native Fucα1-
2Fucα1-3- containing glycans on the array. The lack of binding to native Fucα1-2Fucα1-
3-containing glycans could possibly be due to the fact that double fucoses often occur 
in combination with many more fucosylated elements on the same glycan backbone 
[11], which may hinder the binding of anti-glycan antibodies elicited during FFGn-BSA 
immunization. Compared to FGn, the FFGn glycan motif is more schistosome specific and 
highly antigenic during schistosome exposure and infection, and it would be interesting 
to test whether other synthetic representations of this antigen may induce antibodies 
more reactive with native glycans. 
It is important to realize that in a natural infection, a strong antibody response is 
directed against many multi-fucosylated motifs on N-, O- as well as GSL glycans. The 
difference in magnitude between the simple glycoconjugate vaccination and natural 
infection was clearly observed in the glycan profile of rat antisera 3 weeks post infection 
(Figure 3 and 4). It is intriguing to see that a small, minimal epitope FGn on BSA, elicited 
antibodies to singly fucosylated terminal N-acetylhexosamine, and induced partial 
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protection against S. mansoni infection in rats. 
In conclusion, we have demonstrated that immunization with a fucosylated glycan, 
when conjugated to BSA, induce antibodies that bind to schistosomula and reduce worm 
burden in rats challenged with schistosome infection. Antibodies against fucosylated 
schistosome GSL glycans appear to be associated with the induced protection. Future 
studies should further investigate whether vaccinating with more complex glycan 
antigens and more strongly immunogenic glycan-carrier combinations would generate 
an antibody profile more similar to that observed in protective contexts, and whether that 
would lead to stronger protection in a challenged host.
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Schistosomiasis is the second most socioeconomically devastating parasitic disease after 
malaria, affecting more than 220 million people in endemic countries. The insufficient 
knowledge over schistosome antigens and the host immune response against these 
antigens is a great obstacle towards improving current diagnostic, treatment and 
prevention methods. The studies presented in this thesis focus on mapping the antibody 
response against schistosome glycans whilst the host develops immunity towards 
schistosomiasis. The findings in this thesis provided insight into whether schistosome 
glycans are worth exploiting in the discovery of novel vaccination candidates; as well 
as whether glycan motifs or specific anti-glycan antibody responses can serve as good 
infection markers. 
Antigenic schistosome glycan motifs
A major discussion over anti-glycan antibodies in schistosomiasis is whether they are a 
smokescreen response that directs the host immune response away from recognizing 
essential protein antigens [1-3], or whether glycans can be potential vaccine candidates 
because of their high antigenicity and abundant exposure to the host [4-6]. In chapter 
2 and chapter 3, we investigated longitudinally the IgG and IgM dynamics during the 
development of protection in two different animal models. Chapter 2 described the 
antibody dynamics to glycans in rhesus macaques during the time they naturally clear an 
established infection and at the same time develop resistance to secondary infection [7]. 
Chapter 3 followed the anti-glycan antibody dynamics in baboons when they developed 
protection through repeated radiation-attenuated (RA) cercariae vaccination [2]. The 
use of an elaborate and well defined glycan microarray containing glycans isolated 
from different life stages of S. mansoni to measure antibody responses, instead of crude 
antigens such as soluble egg antigen (SEA) or adult worm antigen (AWA), greatly improved 
the specificity of our results. When using the glycan microarrays, we found that in both 
the baboon and macaque model, IgG response to a small subset of glycans containing 
multiple-fucosylated terminal GalNAcβ1-4GlcNAc (LDN) and Galβ1-4GlcNAc (LN) motifs 
remained high throughout infection clearance and the development of resistance. On the 
other hand, the response to many other non-fucosylated terminal motifs and also to the 
core xylose and core α3-fucose, previously suggested as potential vaccination candidates 
[8] ceased after oviposition. Since core xylose and core α3-fucose have not been found 
on mature worm N-glycans [9], we propose that antibodies against these targets are not 
involved in worm killing, especially since these antibody responses are short lived. It is 
worth noting that core α3-fucose, despite being highly antigenic, is found in schistosomes 
exclusively in eggs, which makes it unsuitable as a vaccine target. Antibodies against 




not serve as good vaccination candidates. A suitable vaccine candidate should be based 
on parasite antigens that are exposed to the host immune system and that are either 
necessary for parasite survival [10] or can form a handle for an antibody-mediated cellular 
anti-parasite response. Although specific roles for highly fucosylated LDN and LN motifs in 
the parasite biology are not known, these antigenic motifs are expressed in all life stages 
of the parasite in different contexts: cercariae and eggs express these motifs on both 
glycoproteins and glycolipids, while adult worms express fucosylated LDN predominantly 
on glycolipids [11, 12]. In all cases these motifs are abundantly present directly at the host-
parasite interface (i.e. at the surface or in secretory systems of the parasite).
In chapter 2 and chapter 3, schistosomula killing assays were used as functional 
assays to assess whether the antibodies generated by macaques and baboons could 
be protective. One of the limitations of our studies was that we did not have enough 
macaque and baboon serum to isolate anti-glycan antibodies in sufficient quantities to 
explore whether anti-glycan antibodies in these sera could be protective in a functional 
assay. Nevertheless, the antibody binding pattern on schistosomula was shown to be 
well correlated with the relative abundance of anti-glycan antibodies, likely against 
highly antigenic multiple-fucosylated LDN motifs. When incubating schistosomula with 
macaque sera in vitro, schistosomula death was positively correlated with the duration of 
infection in the macaques; suggesting the gradual development of potentially protective 
antibodies (chapter 2). For newly transformed schistosomula, it has been shown that they 
can be killed by complement, while 24 h transformed schistosomula became insensitive 
to complement-mediated killing [13]. In our observation, 3 h transformed schistosomula 
were killed by rhesus macaque serum in a complement-independent manner. Higher 
killing percentage was positively associated with tight clustering of the parasites by 
serum antibodies, possibly by hindering physiological mechanisms necessary for parasite 
survival. Unlike rhesus macaque serum, baboon vaccination serum did not lead to any 
killing of the parasite (chapter 3). It is worth noting that most studies on complement 
activation and schistosomula death were performed in vitro. Thus, the in vivo significance 
of complement on schistosomula has not been asserted and other cellular mediated 
defense mechanisms may also play an important role during protection. This could be 
one of the potential reasons why baboon vaccination sera alone was not able to kill 
schistosomula in vitro.  
Since highly fucosylated terminal LDN motifs are specific for schistosomes and 
could induce a long lasting IgG response, we performed a vaccination study to assess 
the protectivity of this glycan motif. Chapter 5 describes a vaccination study in rats 
with synthetic carbohydrates Fucα1-3GlcNAc (FGn) and Fucα1-2Fucα1-3GlcNAc (FFGn) 




with schistosome glycans can reduce worm burden in an S. mansoni infected host. We 
found that immunizing rats with synthetic FGn-BSA together with complete Freund’s 
adjuvant significantly reduced worm burden upon challenge compared to rats vaccinated 
with BSA only. In addition, the antibodies generated by FGn-BSA vaccination recognized 
natural schistosome antigens and were found to bind to the surface of transformed 
schistosomula. The protection induced in rats by 3 consecutive FGn-BSA vaccinations 
was found to be 38% and 29% in two independent experiments (Chapter 5), showing 
that partial protection can be achieved, despite being less effective than some other 
vaccination candidates currently under investigation [14-17]. Future work to improve 
immunization strategies should consider factors such as the time point of infection, route, 
as well as vaccine format. Moreover, the library of potential schistosome glycan candidates 
that can be used in vaccination should be increased. This work however, is challenged by 
the limited availability of native parasite-derived glycoproteins as well as the difficulty 
of synthesizing complex glycan structures. An alternative to create recombinant proteins 
with desired glycosylation is through glycoengineered plants, a maturing technological 
platform [18-20]. Lewis X, LDN and GalNAcβ1-4(Fucα1-3)GlcNAc (LDN-F) glycan motifs 
have been successfully produced on recombinant schistosome proteins in plants by 
fine-tuning the N-glycosylation machinery [19]. Nevertheless, to synthesize multi-fucose 
containing glycans in plants, the fucosyltransferase responsible for generating the 
schistosome specific Fucα1-2Fuc linkage, whether it being a specific α2-fucosyltransferase, 
or another fucosyltransferase with α2-fucosylation activity, needs to be identified [21]. 
Carbohydrate based vaccines have shown success in bacterial infections, and this wave of 
interest is extending to helminth vaccination [22]. Helminths are multicellular organisms 
that go through complex changes both outside and inside the host. 
Till this date, there is no consensus over how an individual develops resistance to 
infection, or what the mechanism of protection is [14, 15]. However, regardless of the 
mechanisms involved, antibodies are seen as key players in the protective immunity 
induced by vaccines [14]. Another important issue hindering vaccine development is the 
lack of clarity in “who is protected” and what the antibody profile of a protected host looks 
like.
What is a protective antibody profile? lessons 
learned from longitudinal studies
The rhesus macaque model (Chapter 2) and the RA cercariae vaccination baboon model 
(Chapter 3) are well known models of protection. Although controlled human infection 
(CHI) models are gaining acceptance, and recently a CHI model for S. mansoni has been 




cohort studies that are non-invasive. Longitudinal studies in non-human primates are 
thus a good complement to human studies by providing the unique opportunity to 
observe the dynamic interplay between host and parasite. We found that upon encounter 
with schistosome antigens, either through experimental cercariae infection, or by RA 
cercariae vaccination, IgM was first elicited and followed by IgG approximately 2-4 weeks 
later. In addition, IgM responses against many glycan epitopes were short lived or lose 
intensity over time, while IgG responses towards specific glycan subsets remained high. 
In experimentally infected rhesus macaques, anti-glycan IgG reached maximum titers 
together with the peak of oviposition at week 8 post infection, while IgM responses towards 
most glycan epitopes decreased after 8 weeks (Chapter 2). This observation in antibody 
dynamics, especially the increase in IgM titers in relation to oviposition is in accordance 
with recent studies in mice that suggested anti-worm and anti-egg IgM to be a good 
measure for acute infection [26]. On the other hand, chronic infections are associated with 
less oviposition and lower parasite specific IgM titers. That being said, IgM titers are not 
solely driven by the presence of eggs, as parasite specific IgM appears much earlier than 
eggs in experimental infections [26, 27], and vaccinating non-human primates with RA 
cercariae induced IgM and IgG responses not only to cercarial preparations [2], but also to 
egg and worm preparations [28, 29], most likely via cross-reactive glycans (Chapter 3) [9]. 
In the vaccination model, high numbers of RA cercariae (in 5 vaccinations) are 
necessary to boost protective IgG titers in baboons (Chapter 3). The anti-cercarial glycan 
IgG titers continued to increase in a saw tooth pattern until vaccination ceased. In contrast, 
the anti-glycan IgM titers were highest after 2 vaccinations, but failed to reach beyond this 
titer with following vaccinations: IgM titers to cercarial glycans either remained constant 
(towards O-glycans) or decreased (towards GSL glycans), likely due to heavy chain class 
switch, indicated by a clear shift in IgM:IgG ratio observed at 10 weeks post vaccination. 
Interestingly, in a different study when baboons were vaccinated 3 times, both IgG and 
IgM responses are high upon challenge infection [30]. In this situation, the vaccination 
efficiency is only 30-54% in contrast to vaccinating 5 times accompanied with decreased 
IgM. Overall, we saw that resistance to reinfection in both animal models, as well as 
the clearance of primary infection in rhesus macaques was associated with low IgM 
and high IgG tires against schistosome glycans. Recent studies in mice have proposed 
that IgG/IgM balances against specific schistosome preparations may be effective for 
differentiating acute/chronic infections [26], although the authors also recognized 
the need to characterize and evaluate specific molecules in crude antigens in order to 
promote increased sensitivity and specificity of the diagnosis. In rhesus macaques, we 
found that at the timepoint where macaques are resistant towards secondary infection, 




glycans on cercarial O-glycans specifically. We suggested that high anti-IgG and low anti-
IgM ratios against these cercarial glycans could facilitate protection mechanisms that 
prevent macaques from being re-infected with cercariae (Chapter 2).
Previous studies have indicated that IgM is possibly a blocking antibody that 
prevents eosinophil mediated cytotoxicity by effective IgG subclasses [1]. Moreover, 
human serum IgM has shown an overall competitive advantage over IgG towards glycans 
and not peptides [31]. Although we have shown in vitro through antibody competition 
experiments that the presence of IgM does not prevent IgG binding to the surface of 
schistosomula (Chapter 3), there is no indication that IgM and IgG recognize different 
glycan targets based on glycan array data. Therefore, it is likely that IgM and IgG are 
competing for the same epitopes, thus emphasizing the importance of IgG/IgM balance 
in a protection profile. 
In addition to IgG and IgM balance, IgG subclass balance and the presence of IgE have 
also been discussed as indicators of schistosomiasis disease state [32-36]. In chapter 4 we 
studied the serum IgG subclass response against a selected panel of core-modified N-glycan 
targets of 41 S. mansoni infected individuals living in an endemic area. We observed that 
while IgG1 and IgG3 recognized a range of different N-glycan core structures, IgG2 and 
IgG4, if present, were specific for core α3-fucose and core xylose. It is worth noting that we 
found large variations between individuals. Previously, sera from the same cohort were 
separated into children and adults and their averaged total IgG and IgM response was 
analyzed on the same array as used in this study [37]. Pronounced differences between 
children and adult anti-glycan IgG were reported: IgG in serum from children, unlike adults, 
bound to core α3-fucose irrespective of the presence of the core xylose motif. However, 
when we analyzed the IgG subclass profile of these individuals separately, it appeared 
that only a minority of individuals had IgG towards core α3-fucose (Chapter 4). We also 
reported that antigenic core xylose and core α3-fucose was not recognized by particular 
IgG subclasses selectively, but dependent on the individuals. Previous studies trying to 
attribute the role of IgG subclasses based on cohort studies also faced the same challenge 
of high individual variability and while some observations are true at a population level, 
they cannot be seen on the individual level [38, 39]. Therefore, we recommend future 
studies to consider the size of the cohort as well as defining disease state and/or other 
infections, knowing that different disease pathologies affect the antibody signatures 
in patients with schistosomiasis [39] and the occurrence of cross-reaction with other 
helminths [40, 41]. Another point of consideration is using suitable probes. It has been 
shown that ELISA-SEA, instead of ELISA-SWAP (Soluble worm preparation), was better at 
detecting S. japonicum infection, irrespective of disease condition [39]. SWAP on the other 







Implications for vaccine candidate discovery and 
diagnostics
The standard method of diagnosing schistosome infection is detection of Schistosoma 
eggs. Both urine filtration [43] (for S. haematobium eggs) and Kato-Katz thick smear 
method (for intestinal schistosome eggs) provide high specificity, being able to distinguish 
different schistosome species, but lack sensitivity to detect light infections even through 
repeated sampling [44]. Schistosome antigens such as schistosome circulating cathodic 
antigen (CCA) [45-51] and circulating anodic antigen (CAA) [52, 53], despite not able 
to distinguish between schistosome species [54], are much more robust in detecting 
light-intensity infections in low-endemic areas and are indicators of an active infection. 
Serological detection of anti-schistosome antibodies can be used to determine whether 
a person has been exposed to schistosomes, though the inability to distinguish between 
active and past infection is also one of the biggest limitations of diagnosing with anti-
schistosome antibodies [55-57]. The main advantage of using anti-schistosome antibodies 
as diagnostic markers is that they can be detected very early after infection, even before 
circulating antigens are released from regurgitating juvenile worms [58] (Chapters 2 and 
3) and is also highly sensitive in detecting infection in low schistosome burden settings 
[59, 60]. Whether schistosome glycans and anti-glycan antibodies can serve as better 
diagnostic markers than existing markers is still under investigation. Cercarial glycans 
that are highly antigenic and abundantly expressed on the glycocalyx may possibly be an 
early detection marker for infection. We saw that as early as 2 weeks post RA vaccination 
(Chapter 3), and 4 weeks post infection of rhesus macaque (Chapter 2), antibodies were 
already generated against schistosome specific glycan motifs, such as highly fucosylated 
LDN/LN motifs (these were timepoints of the first measurement, antibody response could 
occur earlier than measured). On the other hand, antigenic glycan motifs such as core 
α3-fucose and core xylose present on schistosomes are not recommended as diagnostic 
biomarkers due to cross-reaction with glycans present on number of nematodes [61-63], 
other invertebrates [64] and plants [65-67]. 
Apart from being diagnostic biomarker candidates, schistosome glycans also have a 
potential to be vaccination targets. We have already shown that immunizing rats with a 
minimal epitope of fucosylated BSA glycoconjugate led to protection (Chapter 5). One of 
the advantages of using schistosome glycan-based vaccines is that many glycan motifs, 
such as multiple fucosylated motifs, are not only highly antigenic, they are present in 
multiple life stages and expressed by multiple proteins of the parasite, thereby maximizing 
the time frame and abundance in which targets of a vaccine are present in the infected 




motifs are also present on eggs [9].  If an inflammatory immune response to egg glycan 
is triggered in patients with patent infection, it may exacerbate immunopathology. With 
aid of the maturing glycan synthesis technologies, future studies should continue to 
interrogate more specific, differently fucosylated glycan structures and identify those that 
give higher levels of protection, but minimal side effects. 
Conclusion
The studies in this thesis have clearly demonstrated the diversity and complexity of 
anti-glycan antibody responses: not all glycan motifs and not all anti-glycan antibody 
responses are the same. By evaluating schistosome glycan motifs separately, we provided 
new insights into glycan epitopes in the context of vaccination and infection monitoring. 
In addition, we have shown that the anti-glycan antibody responses are highly dynamic 
and versatile: some early, some late, some long-living, others die out fast. Hopefully, the 
studies presented in this thesis has provided some clarity to the complexity of glycan 
epitopes, as well as the antibody responses to them.
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Schistosomiasis is a parasitic disease, caused by infection with Schistosoma worms, that 
ranks second only to malaria in terms of socio-economic and public health impact. Once a 
schistosome infection establishes, the adult worm-pair can reside in the host for decades if 
not treated. Current treatment of schistosomiasis relies mainly on the use of the chemical 
drug Praziquantel (PZQ), even though PZQ cannot prevent the rapid re-infections that 
occur in endemic areas. A prophylactic therapy that can prevent schistosome infection is 
therefore urgently sought for. 
The high prevalence of schistosomiasis in endemic populations indicates that natural 
immunity is rare. To date, although cases of acquired immunity have been reported, there is 
no evidence or consensus regarding how these individuals developed resistance, or what 
the mechanism of resistance is. It is known that in schistosome-infected hosts, antibodies 
are raised to numerous schistosome antigens, of which a majority are antibodies directed 
against schistosome glycan motifs. Schistosomes express a plethora of glycans: some 
glycan structures are expressed in a life-stage specific manner, while others are found 
in multiple life-stages, either secreted, exposed on the surface or expressed internally. 
Interestingly, conflicting views exist over the role of antibodies developed against 
schistosome glycans during infection. While some studies suggest that antibodies against 
schistosome glycans are a ‘smokescreen’ response that prevents the host from recognizing 
vulnerable parasite peptide antigens, others have shown that antigenic schistosome 
glycans could be involved in developing a protective response. These opposing views can 
result from generalization of the many types and structures of glycan motifs expressed by 
schistosomes, and/or the type of antibodies raised against the target. Fortunately, recent 
advances in technology have made it possible to not only separate and characterize 
individual naturally occurring schistosome glycans, but also to print these sometimes 
highly complex glycans isolated from the parasite on microarrays, that can be used further 
to characterise their binding partners, such as serum antibodies, in a high throughput 
manner. The possibility to chemically synthesize defined glycan structures further expands 
the library of glycans that can be analysed with microarray technology, as well as provide 
the opportunity to vaccinate animals with defined glycoconjugates. 
The goal of this thesis is to advance the knowledge on anti-glycan antibody responses 
during a schistosome infection. In chapter 2 and 3, we used glycan-microarrays to follow 
the IgG and IgM antibody dynamics; during which naturally acquired and vaccination 




4, we focused on the IgG subclass response against glycans expressed by schistosomes 
in schistosome infected individuals living in an endemic area. Lastly, chapter 5 describes 
an immunization and challenge experiment, where rats were immunized with defined 
glycoconjugates. A better understanding of anti-glycan antibody responses during 
infection and the development of schistosome resistance could improve current 
schistosomiasis diagnostic methods as well as identify potential vaccine targets. 
Studies described in this thesis
In Chapter 2, the antibody response during the development of schistosome resistance 
was studied in rhesus macaques over a time course of 22 weeks. Unlike humans, rhesus 
macaques are able to naturally rid themselves of schistosome worms after infection 
establishes and acquire immunity towards re-infection around 12 weeks post infection. 
We found that upon experimental infection, macaques responded to schistosome glycans 
first with IgM antibodies, followed by IgG approximately 2-4 weeks later. Through the 
course of infection, IgM responses towards many glycan epitopes were short lived, while 
IgG responses towards specific glycan subsets, namely O-glycans with highly fucosylated 
LDN motifs, remained high throughout worm clearance. In general, glycans with a higher 
degree of fucosylation gave rise to stronger antibody responses than non-fucosylated 
glycans. When incubating macaque serum with schistosomula in vitro, schistosomula 
death was positively correlated with the duration of infection of macaques, suggesting 
presence of potentially protective antibodies. The findings in this chapter suggest that 
IgG antibodies against highly fucosylated LDN motifs that remain when the worms 
deteriorate could be associated with infection clearance and resistance to re-infection in 
macaques.
In Chapter 3, we studied the anti-glycan antibody responses during the development 
of schistosome resistance in baboons vaccinated with radiation-attenuated (RA) cercariae 
over a time course of 25 weeks. We found that both IgM and IgG targeted highly 
antigenic glycan structures with multi-fucosylated GalNAc/GlcNAc motifs expressed 
on cercarial O-glycans and glycosphingolipids (GSL). However, while IgM responses to 
these antigenic schistosome glycan motifs plateaued or decreased after 2 vaccinations, 
each of the 5 consecutive vaccinations boosted the anti-glycan IgG antibody response 
in baboons against these glycan motifs. At the moment of cercarial challenge, 19 weeks 
post vaccination, the IgG response against these multi-fucosylated glycan motifs present 
on cercarial O- and GSL glycans was at its highest, and remained high until 6 weeks post-
challenge. These findings support the hypothesis that anti-glycan IgG is important in 




Particular IgG subclasses have been found to correlate with resistance or susceptibility 
to schistosome infection. In Chapter 4, the IgG subclass response of 41 schistosome infected 
individuals with similar infection intensities was analysed using glycan microarrays. We 
found that highly antigenic glycan motifs, such as multi-fucosylated LDN motifs can be 
recognized by all IgG subclasses, with IgG1 and IgG2 being more predominant. When 
looking at individual response towards core modified N-glycans, IgG2 and IgG4, when 
present, were specific for core α3-fucose and xylose motifs, while IgG1 and IgG3 were 
found against a less restricted range of N-glycan modifications. It is worth noting that 
high inter-individual antibody variation was observed against core modified N-glycans 
expressed by schistosomes. This study is the first to address IgG subclass responses to 
defined glycans in a helminth infection.
Finally, to test whether specific antigenic glycan motifs recognized by schistosome 
infected hosts could be involved in protection against schistosomiasis, a vaccination 
study was performed, described in Chapter 5. We found that immunizing rats with a 
single fucosylated GlcNAc motif conjugated to BSA (FGn-BSA) significantly reduced 
worm burden upon cercarial challenge, when compared to rats vaccinated with BSA only 
or double fucosylated GlcNAc conjugated to BSA (FFGn-BSA). The protection induced 
in rats by 3 consecutive FGn-BSA vaccinations was 38% and 29% in two independent 
experiments. Antibodies elicited by FGn-BSA immunization recognized native glycans 
isolated from schistosomes, mainly against lipid-derived glycans containing terminal 
fucosylated GalNAc/GlcNAc motifs. Moreover, FGn-BSA immunized rat serum antibodies 
bound to the entire surface of 3 hour transformed schistosomula, confirming the presence 
of target glycan epitopes on the schistosomulum. This indicates that antibody-dependent 
mechanisms may be involved in immunity against developing larvae upon challenge 
infection which would account for the protection seen in FGn-BSA immunized rats.
Conclusion
The studies described in this thesis demonstrate the diversity and complexity of anti-
glycan antibody responses during a schistosome infection. Individual glycan motifs are 
different in their antigenicity and antibodies towards particular glycans also go through 
rapid changes throughout infection. By evaluating individual schistosome glycans and 
corresponding antibodies we provided new and detailed insights into the diverse anti-






Schistosomiasis is een ziekte die wordt veroorzaakt door infectie met parasitaire 
Schistosoma wormen. Na malaria is het de parasitaire infectieziekte met de hoogste impact 
op socio-economisch gebied en de volksgezondheid.  Zodra een infectie met Schistosoma 
tot stand is gekomen, kan een volwassen wormpaar jarenlang in de gastheer overleven 
zolang deze niet wordt behandeld. De huidige behandeling van schistosomiasis is met 
het geneesmiddel Praziquantel. Dit middel kan echter een snelle herinfectie, zoals in 
endemische gebieden vaak gebeurt, niet voorkomen. Daarom wordt er naarstig gezocht 
naar een profylactische behandeling die infectie met Schistosoma wél kan voorkomen. 
De hoge prevalentie van schistosomiasis in endemische populaties geeft aan dat 
immuniteit zeldzaam is. Hoewel er voorbeelden zijn van groepen mensen die weerstand 
tegen infectie hebben ontwikkeld, is het niet duidelijk wat het mechanisme daarvoor 
is. Het is bekend dat in individuen die met Schistosoma geïnfecteerd zijn, antilichamen 
opgewekt worden tegen een groot aantal schistosoom antigenen en waarvan het grootste 
deel gericht is tegen glycaanmotieven. Schistosoma brengt een scala aan glycanen 
tot expressie. Sommige glycaan structuren komen in een specifiek levensstadium tot 
expressie terwijl anderen in meerdere stadia worden aangetroffen, hetzij uitgescheiden, 
blootgesteld op het oppervlak, of intern. Er zijn tegenstrijdige inzichten over de rol van 
antilichamen tegen schistosoom glycanen tijdens infectie. Sommige studies suggereren 
dat antilichamen tegen glycanen een rookgordijn vormen die de gastheer belemmeren 
om gevoelige peptide antigenen te herkennen, terwijl anderen laten zien dat antigene 
glycanen betrokken kunnen zijn bij het ontwikkelen van een beschermende reactie. 
Deze tegenstrijdige inzichten kunnen het resultaat zijn van het generaliseren van de 
vele types glycanen en de vele verschillende structuren die Schistosoma tot expressie 
brengt en/of het type antilichamen dat daartegen wordt opgewekt. Gelukkig hebben 
recente technologische vorderingen het mogelijk gemaakt om de verschillende 
natuurlijk voorkomende complexe schistosoom glycanen van elkaar te scheiden en te 
analyseren, om deze vervolgens als microarrays te kunnen printen. Deze arrays kunnen 
vervolgens gebruikt worden om de bindingspartners van glycanen, zoals antilichamen, 
op een efficiënte en snelle manier te kunnen karakteriseren. De lijst met glycanen die 
met microarray geanalyseerd kunnen worden kan nog verder worden aangevuld met 
synthetische glycanen en glycaan deelstructuren. Deze bieden tevens de mogelijkheid 
tot vaccinatiestudies in dieren.




een Schistosoma infectie te vergroten. In hoofdstuk 2 en 3 hebben we glycaan microarrays 
gebruikt om IgG en IgM tijdens natuurlijk verworven en door vaccinatie geïnduceerde 
immuniteit te bestuderen in, respectievelijk, resusapen en bavianen. In hoofdstuk 4 
hebben we ons gericht op de IgG subklassen tegen schistosoom glycanen in geïnfecteerde 
individuen die in een endemisch gebied wonen. Tenslotte beschrijft hoofdstuk 5 een 
immunisatie en infectie experiment waarbij ratten geïmmuniseerd zijn met gedefinieerde 
synthetische glycoconjugaten. Een beter begrip van anti-glycaan antilichamen tijdens 
infectie en de ontwikkeling van resistentie tegen schistosomen kan leiden tot betere 
diagnostische methodes en het identificeren van mogelijke vaccin kandidaten.
Studies beschreven in dit proefschrift
In hoofdstuk 2 werden serum antilichamen bestudeerd tijdens het ontwikkelen van 
resistentie tegen schistosomen in resusapen gedurende 22 weken. In tegenstelling tot 
mensen zijn resusapen in staat om Schistosoma wormen op een natuurlijke manier kwijt 
te raken na infectie. Bovendien ontwikkelen zij na ongeveer 12 weken immuniteit tegen 
herinfectie met Schistosoma. We hebben gevonden dat resusapen na experimentele 
infectie reageren op Schistosoma glycanen met de productie van IgM antilichamen, en 
dat dit ongeveer 2-4 weken later gevolgd wordt door IgG. Tijdens de infectie bleken de 
IgM reacties niet lang te duren terwijl IgG reacties tegen specifieke glycanen (O-glycanen 
met gefucosyleerde LDN motieven) sterk bleven tijdens de klaring van de wormen. In 
het algemeen geven glycanen met een hogere graad van fucosylering een sterkere 
antilichaam reactie dan glycanen met minder of geen fucoses. Wanneer serum van 
geïnfecteerde resusapen in vitro wordt toegevoegd aan schistosomula gaat een deel 
van de schistosomula hierdoor dood. Het aantal schistosomula dat dood gaat is positief 
geassocieerd met de duur van infectie in de resusapen. Dit suggereert dat er mogelijk 
beschermende antilichamen aanwezig zijn in deze sera. De bevindingen in dit proefschrift 
laten zien dat de IgG antilichamen gericht tegen sterk gefucosyleerde LDN motieven, 
die aanwezig blijven nadat de wormen uiteenvallen, mogelijk geassocieerd zijn met de 
klaring van de infectie en bescherming tegen herinfectie in resusapen.
In hoofdstuk 3 hebben we de antilichamen tegen glycanen bestudeerd in bavianen 
die weerstand tegen schistosomen ontwikkelen na vaccinatie met door bestraling 
verzwakte cercariën. We hebben gevonden dat zowel IgG als IgM vooral gericht waren 
tegen glycaan structuren met multi-gefucosyleerde GalNAc/GlcNAc motieven op 
cercariële O-glycanen en glycosfingolipiden. Terwijl  IgM tegen deze antigene glycaan 
structuren weer afnam na 2 vaccinaties, zorgden de 5 vaccinaties voor een steeds verdere 




eerste vaccinatie, was de IgG reactie tegen deze multi-gefucosyleerde glycaanmotieven 
op O-glycanen en glycosfingolipiden het sterktst, en die bleef sterk tot 6 weken na 
infectie. Deze bevindingen ondersteunen de hypothese dat anti-glycaan IgG antilichamen 
belangrijk zijn bij immuniteit tegen Schistosoma infectie in bavianen die met bestraalde 
cercariën zijn gevaccineerd.
Bepaalde IgG subklassen zijn gecorreleerd aan weerstand tegen of juist gevoeligheid 
voor een Schistosoma infectie. In hoofdstuk 4 zijn de IgG subklassen van 41 geïnfecteerde 
individuen met vergelijkbare intensiteit van infectie geanalyseerd met behulp van 
glycaan microarrays. We hebben gevonden dat antigene glycaanmotieven, zoals multi-
gefucosyleerd LDN, door alle IgG subklassen herkend kunnen worden en waarbij IgG1 en 
IgG2 overheersten. Wanneer gekeken werd naar de individuele reacties tegen N-glycanen 
bleek dat IgG2 en IgG4, indien deze aantoonbaar aanwezig waren, specifiek gericht 
waren tegen α3-fucose en xylose motieven op de N-glycaan basisstructuur. IgG1 en IgG3, 
daarentegen, waren gericht tegen een bredere reeks van N-glycaan structuren. Het is de 
moeite waard om te vermelden dat er grote variatie tussen individuen is gevonden in 
de antilichamen tegen N-glycaan basisstructuren die schistomen tot expressie brengen. 
Deze studie is de eerste die IgG subklasse reacties tegen glycanen laat zien gedurende 
een infectie met een parasitaire worm. 
In hoofdstuk 5 is een vaccinatie studie beschreven waarin wordt getest of antigene 
glycaanmotieven die herkend worden door het immuunsysteem van de geïnfecteerde 
gastheer gebruikt kunnen worden om bescherming tegen schistosomiasis te verkrijgen. 
We hebben gevonden dat het aantal wormen dat zich ontwikkeld na infectie met cercariën 
significant verlaagd was in ratten die geïmmuniseerd waren met een enkel-gefucosyleerd 
GlcNAc dat geconjugeerd was aan BSA (FGn-BSA) ten opzichte van ratten die alleen 
gevaccineerd waren met BSA of met dubbel gefucosyleerd GlcNAc geconjugeerd aan 
BSA (FFGn-BSA). De bescherming die in ratten geïnduceerd werd door 3 opeenvolgende 
vaccinaties met FGn-BSA was 38% en 29% in twee onafhankelijk uitgevoerde experimenten. 
Antilichamen die opgewekt waren door immunisatie met FGn-BSA bleken in staat om 
natieve glycanen uit schistosomen te herkennen, met name de glycosfingolipide glycanen 
die een gefucosyleerd GalNAc of GlcNAc motief op het uiteinde bevatten. Bovendien 
waren antilichamen in sera van met FGn-BSA geïmmuniseerde ratten in staat om aan 
het gehele oppervlak van 3 uur oude schistosomula te binden, wat de aanwezigheid van 
glycaan epitopen op schistosomula bevestigt. Dit geeft aan dat antilichaam-afhankelijke 
mechanismen betrokken kunnen zijn bij de immuniteit tegen zich ontwikkelende larven 





De studies die beschreven staan in dit proefschrift laten de diversiteit en complexiteit 
van anti-glycaan antilichamen tijdens een Schistosoma infectie zien. Individuele 
glycaanmotieven zijn verschillend in hun antigeniciteit en antilichamen tegen bepaalde 
glycanen ondergaan snelle veranderingen gedurende infectie. Door individuele 
schistosoom Schistosoma glycanen en bijbehorende antilichamen te evalueren hebben 
we nieuwe inzichten verkregen in verschillende anti-glycaan antilichaam reacties die 
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